Substituted Amide Macrocycles with Orexin-2 Receptor Agonist Activity

JP2024516633A5Active Publication Date: 2024-11-27ALKERMES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023565387
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-26
Filing Date
2022-04-25
Publication Date
2024-11-27
Estimated Expiration
2042-04-25

AI Technical Summary

Technical Problem

Existing compounds with orexin-2 receptor agonist activity are unsatisfactory in terms of activity, pharmacokinetics, brain/central nervous system penetration, and safety, necessitating the development of improved compounds for treating conditions such as narcolepsy and Parkinson's disease.

Method used

Development of substituted macrocycles, specifically compounds of Formula I-A and Formula II-A, which exhibit orexin-2 receptor agonist activity, modulating the orexin-2 receptors to treat narcolepsy and cataplexy.

Benefits of technology

The substituted macrocycles effectively modulate orexin-2 receptors, providing a therapeutic option for narcolepsy and cataplexy with improved activity, pharmacokinetics, and safety profiles.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides compounds of formula (I) useful for treating narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Application No. 63 / 179,616, filed April 26, 2021, the entire contents of which are incorporated herein by reference.

[0002] Technical Field The present invention relates to substituted macrocyclic compounds, in particular to substituted macrocyclic compounds having agonistic activity. [Background technology]

[0003] 2. Background of the Invention Orexin is a neuropeptide synthesized and released by a subpopulation of neurons in the lateral hypothalamus and surrounding regions. It consists of two subtypes: orexin A and orexin B. Orexin A and orexin B bind to orexin receptors, which are G protein-coupled receptors preferentially expressed in the brain. There are two subtypes of orexin receptors, type 1 and type 2 (Cell, Vol. 92, 573-585, 1998). Activation of orexin receptors is known to be important for various central nervous system functions such as sustained wakefulness, energy homeostasis, reward processing, and motivation (Saper et al., TRENDS in Neuroscience 2001;Yamanaka et al., Neuron 2003;Sakurai, Nature Reviews Neuroscience 2014).

[0004] Narcolepsy is a neurological disorder that results in excessive daytime sleepiness, sudden attacks of muscle paralysis (cataplexy), and disrupted sleep patterns (Mahoney et al., Nature Reviews Neuroscience, 2019). Narcolepsy is known to be caused by the degeneration of orexin neurons. Narcoleptic symptoms can be modeled in transgenic mice genetically engineered to degenerate orexin neurons, and the symptoms can be reversed by intraventricular administration of orexin peptides (Proc. Natl. Acad. Sci. USA, Vol. 101, 4649-4654, 2004). Studies of orexin-2 receptor knockout mice suggest that the orexin-2 receptor plays a preferential role in maintaining wakefulness (Cell, Vol. 98, 437-451, 1999, Neuron, Vol. 38, 715-730, 2003). Thus, orexin-2 receptor agonists may be therapeutic agents for other disorders exhibiting excessive daytime sleepiness, such as narcolepsy or Parkinson's disease (CNS Drugs, Vol. 27, 83-90, 2013; Brain, Vol. 130, 2007, 1586-1595).

[0005] Compounds having agonist activity at the orexin-2 receptor are hypothesized to be useful as novel therapeutic agents for conditions such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndromes, disturbances in consciousness such as coma, narcolepsy syndromes, hypersomnolence syndromes characterized by excessive sleepiness (e.g. in Parkinson's disease, Guillain-Barré syndrome or Kleine-Lewin syndrome), Alzheimer's disease, obesity, insulin resistance syndromes, heart failure, diseases associated with bone loss or sepsis. (Cell Metabolism, Vol. 9, 64-76, 2009;Neuroscience, Vol. 121, 855-863, 2003;Respiration, Vol. 71, 575-579, 2004;Peptides, Vol. 23, 1683-1688, 2002;WO 2015 / 073707;Journal of the American College of Cardiology, Vol. 66, 2015, pages 2522-2533;WO 2015 / 048091;WO 2015 / 147240).

[0006] Several compounds with orexin-2 receptor agonist activity have been reported (US Pat. No. 8,258,163; WO 2015 / 088000; WO 2014 / 198880; Journal of Medicinal Chemistry, Vol. 58, pages 7931-7937; US 20190040010; US 20190031611; US ​​20170226137). However, these compounds are considered to be unsatisfactory, for example, in terms of activity, pharmacokinetics, brain / central nervous system penetration or safety, and the development of improved compounds with orexin-2 receptor agonist activity is desirable. Summary of the Invention

[0007] Summary of the Invention The present invention contemplates providing substituted macrocyclic compounds that have orexin-2 receptor agonist activity.

[0008] Thus, in a first aspect, the present invention provides a compound of formula IA: [ka] or a pharma- ceutically acceptable salt thereof, wherein: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14, R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0009] In one embodiment, a compound of formula I: [ka] Provided herein are compounds of formula IA having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0010] Formula II-A: [ka] Also provided herein is a compound having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; When Y is absent, m is 2, 3, 4, or 5; or Y is NR 10 or when O, m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0011] In one embodiment, a compound of formula II: [ka] Provided herein is a compound of formula II-A having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; When Y is absent, m is 2, 3, 4, or 5; or Y is NR 10 or when O, m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0012] Also provided herein is a pharmaceutical composition comprising a compound of any of Formulas IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0013] In another aspect, provided herein is a method of treating narcolepsy in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0014] In another aspect, provided herein is a method of treating cataplexy in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Detailed Description of the Invention Provided herein are compounds useful for treating narcolepsy or cataplexy in a subject, such as compounds of formula IA, I, II-A, or II, or a pharma- ceutically acceptable salt thereof.

[0016] In a non-limiting aspect, these compounds can modulate orexin-2 receptor. In certain embodiments, the compounds provided herein are considered to be orexin-2 agonists. Thus, in one aspect, the compounds provided herein are useful for treating narcolepsy in a subject by acting as an agonist of orexin-2 receptor.

[0017] definition Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout the specification and claims, unless otherwise limited in specific examples, either individually or as part of a larger group.

[0018] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry and peptide chemistry are those well known and commonly used in the art.

[0019] As used herein, the articles "a" and "an" refer to one or to more than one (i.e., at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. Furthermore, use of the terms "including" as well as other forms such as "include," "includes," and "included" are not limiting.

[0020] As used herein, the term "about" is understood by those skilled in the art and varies to some extent depending on the context in which it is used. As used herein, when referring to a measurable value, such as an amount, a time duration, etc., the term "about" means to include a variation of ±20% or ±10%, such as ±5%, ±1% and ±0.1% from the specified value, such that such variation is appropriate for carrying out the disclosed method.

[0021] As used herein, the term "EC 50 " refers to the concentration of a compound required to achieve an effect that is 50% of the maximal observed effect of that compound.

[0022] The term "agonist," as used herein, refers to a compound that, when contacted with a target of interest (e.g., an orexin-2 receptor), produces an increase in the magnitude of a particular activity or function of the target compared to the magnitude of the activity or function observed in the absence of the agonist.

[0023] The terms "treat," "treated," "treating," or "treatment" include the decrease or alleviation of at least one symptom associated with or caused by the condition, disorder, or disease being treated. In certain embodiments, treatment involves contacting the orexin-2 receptor with an effective amount of a compound of the invention for conditions associated with narcolepsy or cataplexy.

[0024] As used herein, the term "prevent" or "prevention" refers to the absence of onset of a disorder or disease in the absence of any previous occurrence, or the absence of further onset of a disorder or disease in the absence of an onset of a disorder or disease already present. The ability to prevent some or all of the symptoms associated with a disorder or disease is also considered.

[0025] As used herein, the terms "patient", "individual" or "subject" refer to a human or non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Preferably, the patient, subject or individual is a human.

[0026] As used herein, the terms "effective amount," "pharmaceutical effective amount," and "therapeutically effective amount" refer to a non-toxic but sufficient amount of an agent to provide a desired biological result. This result may be a reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. The appropriate therapeutic amount in any individual case may be determined by one of skill in the art using routine experimentation.

[0027] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0028] As used herein, the term "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds, where the parent compound is modified by converting an acid or base moiety present to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include conventional non-toxic salts of the parent compound formed, for example, with non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. The phrase "pharmaceutically acceptable salts" is not limited to mono or 1:1 salts. For example, "pharmaceutically acceptable salts" also include bis salts, such as bis hydrochloride salts. Lists of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated by reference in its entirety.

[0029] As used herein, the term "composition" or "pharmaceutical composition" refers to a mixture of at least one compound useful in the present invention with a pharmaceutically acceptable carrier. Pharmaceutical compositions facilitate the administration of compounds to patients or subjects. There are multiple techniques of administering compounds in the art, including but not limited to intravenous, oral, aerosol, parenteral, intraocular, pulmonary and topical administration.

[0030] As used herein, the term "pharmaceutical acceptable carrier" refers to a pharmaceutically acceptable substance, composition or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent or encapsulating substance, involved in carrying or transporting a compound useful in the present invention into or to a patient so that it can perform its intended function. Typically, such constructs are carried or transported from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other components of the formulation, such as the compound useful in the present invention, and not toxic to the patient. Some examples of materials which may serve as pharma- ceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository wax; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffered solutions; and other non-toxic compatible substances used in pharmaceutical formulations.

[0031] As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, absorption delaying agents, and the like, that are compatible with the activity of the compound useful in the present invention and are physiologically acceptable to the patient. Supplementary active compounds can also be incorporated into the composition. "Pharmaceutically acceptable carrier" can also include pharmaceutically acceptable salts of the compound useful in the present invention. Other additional components that can be included in the pharmaceutical compositions used in the practice of the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0032] As used herein, the term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon having the indicated number of carbon atoms (i.e., C 1-6 Alkyl means alkyl having 1 to 6 carbon atoms), including straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl and hexyl. Other examples of C1-C6-alkyl include ethyl, methyl, isopropyl, isobutyl, n-pentyl and n-hexyl.

[0033] As used herein, the terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably fluorine, chlorine or bromine, and more preferably fluorine or chlorine.

[0034] As used herein, the term "alkylene" refers to a divalent aliphatic hydrocarbyl group, e.g., having 1 to 4 carbon atoms, which is either straight-chained or branched. This term includes, by way of example, methylene (-CH-), ethylene (-CHCH-), n-propylene (-CHCHCH-), iso-propylene (-CHCH(CH)-), and the like.

[0035] As used herein, the term "alkenyl" refers to a monovalent group derived from a hydrocarbon moiety containing at least two carbon atoms and at least one carbon-carbon double bond. The double bond may or may not be the point of attachment to another group. Alkenyl groups (e.g., C2-C8-alkenyl) include, but are not limited to, for example, ethenyl, propenyl, prop-1-en-2-yl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.

[0036] As used herein, the term "alkynyl" refers to a monovalent group derived from a hydrocarbon moiety containing at least two carbon atoms and at least one carbon-carbon triple bond. The triple bond may or may not be the point of attachment to another group. Alkynyl groups (e.g., C2-C8-alkynyl) include, but are not limited to, ethynyl, propynyl, prop-1-yn-2-yl, butynyl, 1-methyl-2-butyn-1-yl, heptenyl, octynyl, and the like.

[0037] As used herein, the term "alkoxy" refers to the group -O-alkyl, where alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, t-butoxy, and the like.

[0038] As used herein, the term "cycloalkyl" refers to a non-aromatic carbocyclic ring system that is partially or fully saturated and has one, two or three rings, where such rings may be fused. The term "fused" means that a second ring is present (i.e., linked or formed) by having two adjacent atoms in common (i.e., shared) with the first ring. Cycloalkyl also includes bicyclic structures that may be bridged or spirocyclic in nature, with each individual ring within the bicycle varying from 3 to 8 atoms. The term "cycloalkyl" includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[3.1.0]hexyl, spiro[3.3]heptanyl, and bicyclo[1.1.1]pentyl.

[0039] As used herein, the term "heterocyclyl" means a non-aromatic carbocyclic ring system containing 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S, and having 1, 2, or 3 rings, where such rings may be fused, where fusion is defined above. Heterocyclyl also includes bicyclic structures which may be bridged or spirocyclic in nature, where each individual ring within the bicycle varies from 3 to 8 atoms and contains 0, 1, or 2 N, O, or S atoms. The term "heterocyclyl" includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams), and specifically includes, but is not limited to, epoxyzyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiazinanyl, and the like. For example, the term "heterocyclyl" can include a 4- to 10-membered heterocyclyl, a 4- to 7-membered heterocyclyl, a 5- to 10-membered heterocyclyl, a 6- to 10-membered heterocyclyl, a 4- to 6-membered heterocyclyl, a 4-membered heterocyclyl, a 5-membered heterocyclyl, a 6-membered heterocyclyl, a 7-membered heterocyclyl, an 8-membered heterocyclyl, a 9-membered heterocyclyl, or a 10-membered heterocyclyl.

[0040] As used herein, the term "aromatic" refers to a carbocyclic or heterocyclic ring having one or more polyunsaturated rings and having aromatic character, i.e., having (4n+2) delocalized π (pi) electrons, where n is an integer.

[0041] As used herein, the term "aryl" refers to an aromatic carbocyclic ring system containing one, two or three rings, where such rings may be fused, fused being defined above. When rings are fused, one of the rings may be fully unsaturated, and the fused ring(s) may be fully saturated, partially unsaturated or fully unsaturated. The term "aryl" includes, but is not limited to, phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthalenyl. For example, the term "aryl" includes C6-C 10 It may include aryl, C6-C8 aryl or C6 aryl (i.e. phenyl).

[0042] As used herein, the term "heteroaryl" refers to an aromatic carbocyclic ring system containing 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S, and having 1, 2, or 3 rings, where such rings may be fused, fusion being defined above. The term "heteroaryl" includes, but is not limited to, furanyl, thiophenyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and the like. For example, the term "heteroaryl" can include 5-10 membered heteroaryl, 5-8 membered heteroaryl, 5-6 membered heteroaryl, 6-10 membered heteroaryl, 6-8 membered heteroaryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, or 10 membered heteroaryl.

[0043] Where an aryl, heteroaryl, cycloalkyl, or heterocyclyl moiety may be bonded or otherwise attached to the depicted moiety through different ring atoms (i.e., shown or described without indication of a particular point of attachment), it is understood that all possible points, whether through a carbon atom or, for example, a trivalent nitrogen atom, are intended. For example, the term "pyridinyl" means 2-, 3-, or 4-pyridinyl, the term "thiophenyl" means 2- or 3-thiophenyl, etc.

[0044] As used herein, the term "substituted" means that an atom or group of atoms has a hydrogen replaced as a substituent attached to another group.

[0045] Compounds of the Invention Thus, in a first aspect, the present invention provides a compound of formula IA: [ka] or a pharma- ceutically acceptable salt thereof, wherein: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0046] In one embodiment, a compound of formula I: [ka] Provided herein are compounds of formula IA having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0047] In one embodiment of Formula (I), n is 1. In another embodiment of Formula (I), n is 2. In another embodiment of Formula (I), n is 3.

[0048] In another embodiment of formula (I), ring A is phenyl. In another embodiment of formula (I), ring A is pyridinyl. In another embodiment of formula (I), ring A is pyridazinyl. In another embodiment of formula (I), ring A is pyrimidinyl. In another embodiment of formula (I), ring A is pyrazinyl. In another embodiment of formula (I), ring A is triazinyl.

[0049] In another embodiment of formula (I), Y is NR 10 In another embodiment of formula (I), Y is O. In another embodiment of formula (I), Y is absent. In another embodiment of formula (I), ring A is phenyl and Y is NR 10 In another embodiment of formula (I), ring A is phenyl and Y is O. In another embodiment of formula (I), ring A is phenyl and Y is absent. In another embodiment of formula (I), ring A is pyridinyl and Y is NR 10 In another embodiment of formula (I), ring A is pyridinyl and Y is O. In another embodiment of formula (I), ring A is pyridinyl and Y is absent. In another embodiment of formula (I), ring A is pyridazinyl and Y is NR 10 In another embodiment of formula (I), ring A is pyridazinyl and Y is O. In another embodiment of formula (I), ring A is pyridazinyl and Y is absent. In another embodiment of formula (I), ring A is pyrimidinyl and Y is NR 10 In another embodiment of formula (I), ring A is pyrimidinyl and Y is O. In another embodiment of formula (I), ring A is pyrimidinyl and Y is absent. In another embodiment of formula (I), ring A is pyrazinyl and Y is NR 10 In another embodiment of formula (I), ring A is pyrazinyl and Y is O. In another embodiment of formula (I), ring A is pyrazinyl and Y is absent. In another embodiment of formula (I), ring A is triazinyl and Y is NR 10 In another embodiment of formula (I), ring A is triazinyl and Y is O. In another embodiment of formula (I), ring A is triazinyl and Y is absent.

[0050] In another embodiment of formula (I), T is CR1R2. In another embodiment of formula (I), T is O. In another embodiment of formula (I), W is CR4R5. In another embodiment of formula (I), W is O. In another embodiment of formula (I), T is CR1R2 and W is CR4R5. In another embodiment of formula (I), T is O and W is CR4R5. In another embodiment of formula (I), T is CR1R2 and W is O.

[0051] In another embodiment of formula (I), V is CR3. In another embodiment of formula (I), V is N.

[0052] In another embodiment of formula (I), T is CR1R2 and V is CR3. In another embodiment of formula (I), T is O and V is CR3. In another embodiment of formula (I), T is CR1R2 and V is N. In another embodiment of formula (I), T is O and V is N.

[0053] In another embodiment of formula (I), W is CR4R5 and V is CR3. In another embodiment of formula (I), W is O and V is CR3. In another embodiment of formula (I), W is CR4R5 and V is N. In another embodiment of formula (I), W is O and V is N.

[0054] In another embodiment of formula (I), T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (I), T is CR1R2, W is O, and V is CR3. In another embodiment of formula (I), T is CR1R2, W is CR4R5, and V is N. In another embodiment of formula (I), T is CR1R2, W is O, and V is N. In another embodiment of formula (I), T is O, W is CR4R5, and V is CR3.

[0055] In another embodiment of formula (I), E is NR a R b In another embodiment of formula (I), E is C(=O)NR a R bIn another embodiment of formula (I), E is C1-C3 alkylene-NR a R b In another embodiment of formula (I), E is unsubstituted C1-C3 alkyl, unsubstituted C2-C4 alkenyl or unsubstituted C2-C4 alkynyl. In another embodiment of formula (I), E is C1-C3 alkyl, C2-C4 alkenyl or C2-C4 alkynyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is unsubstituted C1-C3 alkyl. In another embodiment of formula (I), E is C1-C3 alkyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is unsubstituted C3-C8 cycloalkyl. In another embodiment of formula (I), E is C3-C8 cycloalkyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is unsubstituted C1-C3 alkylene-(C3-C8 cycloalkyl). In another embodiment of formula (I), E is C1-C3 alkylene-(C3-C8 cycloalkyl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is unsubstituted 4-10 membered heterocyclyl. In another embodiment of formula (I), E is 4-10 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is unsubstituted C1-C3 alkylene-(4-10 membered heterocyclyl). In another embodiment of formula (I), E is C1-C3 alkylene-(4-10 membered heterocyclyl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is an unsubstituted C6-C 10 In another embodiment of formula (I), E is a C6-C aryl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. 10In another embodiment of formula (I), E is an unsubstituted C1-C3 alkylene-(C6-C 10 In another embodiment of formula (I), E is C1-C3 alkylene-(C6-C aryl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. 10 In another embodiment of formula (I), E is an unsubstituted 5-10 membered heteroaryl. In another embodiment of formula (I), E is a 5-10 membered heteroaryl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0056] In another embodiment of formula (I), E is an unsubstituted 4-7 membered heterocyclyl. In another embodiment of formula (I), E is a 4-7 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is an unsubstituted 4-6 membered heterocyclyl. In another embodiment of formula (I), E is a 4-6 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is an unsubstituted 4 membered heterocyclyl. In another embodiment of formula (I), E is a 4 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is an unsubstituted 5-membered heterocyclyl. In another embodiment of formula (I), E is a 5-membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is an unsubstituted 6-membered heterocyclyl. In another embodiment of formula (I), E is a 6-membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0057] In another embodiment of formula (I), E is NR a R b , C(=O)NR a R b, C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0058] In another embodiment of formula (I), E is C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0059] In another embodiment of formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0060] In another embodiment of formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl or C1-C3 alkylene-(4-10 membered heterocyclyl), where C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl or C1-C3 alkylene-(4-10 membered heterocyclyl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0061] In another embodiment of formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl), wherein C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0062] In another embodiment of formula (I), E is methyl, wherein methyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is methyl. In another embodiment of formula (I), E is trifluoromethyl. In another embodiment of formula (I), E is dioxanyl, wherein dioxanyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is tetrahydropyranyl, wherein tetrahydropyranyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is tetrahydrofuranyl, wherein tetrahydrofuranyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is azetidinyl, where azetidinyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is oxetanyl, where oxetanyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (I), E is morpholinyl, where morpholinyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0063] In another embodiment of formula (I), R 14 is H. In another embodiment of formula (I), R 14 is unsubstituted C1-C3 alkyl. In another embodiment of formula (I), R 15 and R 16 are each H. In another embodiment of formula (I), R 15 is unsubstituted C1-C3 alkyl, R 16 is H. In another embodiment of formula (I), R 16is unsubstituted C1-C3 alkyl, R 15 is H. In another embodiment of formula (I), each R 17 and R 18 is H. In another embodiment of formula (I), R 17 is unsubstituted C1-C3 alkyl, R 18 is H. In another embodiment of formula (I), R 18 is unsubstituted C1-C3 alkyl, R 17 is H. In another embodiment of formula (I), R 14 , R 15 , R 16 , R 17 and R 18 is an unsubstituted C1-C3 alkyl and the others are each H.

[0064] In another embodiment of formula (I), m is 1. In another embodiment of formula (I), m is 2. In another embodiment of formula (I), m is 3. In another embodiment of formula (I), m is 4. In another embodiment of formula (I), m is 1, 2 or 3. In another embodiment of formula (I), m is 2, 3 or 4. In another embodiment of formula (I), m is 1 or 2. In another embodiment of formula (I), m is 3 or 4.

[0065] In another embodiment of formula (I), Y is O and m is 1. In another embodiment of formula (I), Y is O and m is 2. In another embodiment of formula (I), Y is O and m is 3. In another embodiment of formula (I), Y is O and m is 4. In another embodiment of formula (I), Y is O and m is 1, 2 or 3. In another embodiment of formula (I), Y is O and m is 2, 3 or 4. In another embodiment of formula (I), Y is O and m is 1 or 2. In another embodiment of formula (I), Y is O and m is 3 or 4.

[0066] In another embodiment of formula (I), Y is absent and m is 1. In another embodiment of formula (I), Y is absent and m is 2. In another embodiment of formula (I), Y is absent and m is 3. In another embodiment of formula (I), Y is absent and m is 4. In another embodiment of formula (I), Y is absent and m is 1, 2 or 3. In another embodiment of formula (I), Y is absent and m is 2, 3 or 4. In another embodiment of formula (I), Y is absent and m is 1 or 2. In another embodiment of formula (I), Y is absent and m is 3 or 4.

[0067] In another embodiment of formula (I), Y is NR 10 and m is 1. In another embodiment of formula (I), Y is NR 10 and m is 2. In another embodiment of formula (I), Y is NR 10 and m is 3. In another embodiment of formula (I), Y is NR 10 and m is 4. In another embodiment of formula (I), Y is NR 10 and m is 1, 2 or 3. In another embodiment of formula (I), Y is NR 10 and m is 2, 3 or 4. In another embodiment of formula (I), Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), Y is NR 10 and m is 3 or 4.

[0068] In another embodiment of formula (I), ring A is phenyl and n is 1. In another embodiment of formula (I), ring A is phenyl and n is 2. In another embodiment of formula (I), ring A is phenyl and n is 3. In another embodiment of formula (I), ring A is pyridinyl and n is 1. In another embodiment of formula (I), ring A is pyridinyl and n is 2. In another embodiment of formula (I), ring A is pyridinyl and n is 3. In another embodiment of formula (I), ring A is pyridazinyl and n is 1. In another embodiment of formula (I), ring A is pyridazinyl and n is 2. In another embodiment of formula (I), ring A is pyridazinyl and n is 3. In another embodiment of formula (I), ring A is pyrimidinyl and n is 1. In another embodiment of formula (I), ring A is pyrimidinyl and n is 2. In another embodiment of formula (I), ring A is pyrimidinyl and n is 3. In another embodiment of formula (I), ring A is pyrazinyl and n is 1. In another embodiment of formula (I), ring A is pyrazinyl and n is 2. In another embodiment of formula (I), ring A is pyrazinyl and n is 3. In another embodiment of formula (I), ring A is triazinyl and n is 1. In another embodiment of formula (I), ring A is triazinyl and n is 2. In another embodiment of formula (I), ring A is triazinyl and n is 3.

[0069] In another embodiment of formula (I), ring A is phenyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is phenyl, n is 2 and Y is NR 10 In another embodiment of formula (I), ring A is phenyl, n is 3 and Y is NR 10In another embodiment of formula (I), ring A is phenyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is phenyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is phenyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is phenyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is phenyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is phenyl, n is 3, and Y is absent.

[0070] In another embodiment of formula (I), ring A is phenyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 3 and Y is NR 10and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, n is 3, Y is absent, and m is 3 or 4.

[0071] In another embodiment of formula (I), ring A is pyridinyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is pyridinyl, n is 2 and Y is NR 10 In another embodiment of formula (I), ring A is pyridinyl, n is 3 and Y is NR 10 In another embodiment of formula (I), ring A is pyridinyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is pyridinyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is pyridinyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is pyridinyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is pyridinyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is pyridinyl, n is 3, and Y is absent.

[0072] In another embodiment of formula (I), ring A is pyridinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 3 and Y is NR 10and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridinyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridinyl, n is 3, Y is absent, and m is 3 or 4.

[0073] In another embodiment of formula (I), ring A is pyridazinyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is pyridazinyl, n is 2 and Y is NR 10In another embodiment of formula (I), ring A is pyridazinyl, n is 3 and Y is NR 10 In another embodiment of formula (I), ring A is pyridazinyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is pyridazinyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, and Y is absent.

[0074] In another embodiment of formula (I), ring A is pyridazinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyridazinyl, n is 1 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 2 and Y is NR 10and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4.

[0075] In another embodiment of formula (I), ring A is pyrimidinyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is pyrimidinyl, n is 2 and Y is NR 10 In another embodiment of formula (I), ring A is pyrimidinyl, n is 3 and Y is NR 10 In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, and Y is absent.

[0076] In another embodiment of formula (I), ring A is pyrimidinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2 and Y is NR10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4.

[0077] In another embodiment of formula (I), ring A is pyrazinyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is pyrazinyl, n is 2 and Y is NR 10 In another embodiment of formula (I), ring A is pyrazinyl, n is 3 and Y is NR 10 In another embodiment of formula (I), ring A is pyrazinyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, and Y is absent.

[0078] In another embodiment of formula (I), ring A is pyrazinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, and Y is NR10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.

[0079] In another embodiment of formula (I), ring A is triazinyl, n is 1 and Y is NR 10 In another embodiment of formula (I), ring A is triazinyl, n is 2 and Y is NR 10 In another embodiment of formula (I), ring A is triazinyl, n is 3 and Y is NR 10 In another embodiment of formula (I), ring A is triazinyl, n is 1, and Y is O. In another embodiment of formula (I), ring A is triazinyl, n is 2, and Y is O. In another embodiment of formula (I), ring A is triazinyl, n is 3, and Y is O. In another embodiment of formula (I), ring A is triazinyl, n is 1, and Y is absent. In another embodiment of formula (I), ring A is triazinyl, n is 2, and Y is absent. In another embodiment of formula (I), ring A is triazinyl, n is 3, and Y is absent.

[0080] In another embodiment of formula (I), ring A is triazinyl, n is 1 and Y is NR10 and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (I), ring A is triazinyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (I), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4.

[0081] In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 1. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 3. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 1. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 3.

[0082] In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and Y is O. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and Y is O. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.

[0083] In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.In another embodiment of formula (I), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4. In another embodiment of formula (I), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4.

[0084] In another embodiment of formula (I), p is 0 and R1, R2, R4 and R5 are each H. In another embodiment of formula (I), p is 0; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (I), p is 0; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 In another embodiment of formula (I), p is 0; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are H and R 12 and R 13 are H, respectively.

[0085] In another embodiment of formula (I), p is 1 and R1, R2, R4 and R5 are each H. In another embodiment of formula (I), p is 1; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (I), p is 1; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are each H. In another embodiment of formula (I), p is 1; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R11 are H and R 12 and R 13 are H, respectively.

[0086] In another embodiment of formula (I), p is 2 and R1, R2, R4 and R5 are each H. In another embodiment of formula (I), p is 2; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (I), p is 2; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 In another embodiment of formula (I), p is 2; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are H and R 12 and R 13 are H, respectively.

[0087] In another embodiment of formula (I), p is 1, 2, 3 or 4 and R is fluorine. In another embodiment of formula (I), p is 1, 2, 3 or 4 and R is deuterium. In another embodiment of formula (I), p is 1, 2, 3 or 4 and each R is independently selected from the group consisting of hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium. In another embodiment of formula (I), p is 1, 2, 3 or 4 and each R is independently selected from the group consisting of cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium. In another embodiment of formula (I), p is 1 and R is unsubstituted C1-C3 alkyl. In another embodiment of formula (I), p is 1 and R is methyl. In another embodiment of formula (I), p is 1 or 2 and each R is methyl. In another embodiment of formula (I), p is 1 and R is C1-C3 alkyl substituted with one or more halogens. In another embodiment of formula (I), p is 1 and R is CF3. In another embodiment of formula (I), p is 1 or 2 and each R is CF3.

[0088] In another embodiment of formula (I), one or more of R1, R2, R4, and R5 are fluorine. In another embodiment of formula (I), one or more of R1, R2, R4, and R5 are deuterium. In another embodiment of formula (I), R6, R7, R8, R9, and R 11 In another embodiment of formula (I), one or more of R, R, R, R and R 11 In another embodiment of formula (I), one or more of R 12 and R 13 In another embodiment of formula (I), one or more of R 12 and R 13 One or more of is deuterium.

[0089] In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 is H. In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 is H and m is 1. In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 14 , R 15 , R 16 , R 17 and R 18 is H. In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 14 , R 15 , R 16 , R 17 and R 18 is H and m is 1. In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R18 is H. In another embodiment of formula (I), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 is H and m is 1.

[0090] Each of the embodiments described herein with respect to compounds of formula I also applies to compounds of formula IA.

[0091] Formula II-A: [ka] Also provided herein is a compound having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R a and R b are each independently H or unsubstituted C1-C3 alkyl; When Y is absent, m is 2, 3, 4, or 5; or Y is NR 10 or when O, m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0092] In one embodiment, a compound of formula II: [ka] Provided herein is a compound of formula II-A having the structure: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b, C(=O)NR a R b , C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl and C1-C3 alkylene-(5-10 membered heteroaryl), wherein C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl, C1-C3 alkylene-(C6-C 10 aryl), 5-10 membered heteroaryl or C1-C3 alkylene-(5-10 membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl; T is CR1R2 or O; W is CR4R5 or O; U is CR6R7; X is CR8R9; V is CR3 or N; Y is NR 10 , O or non-existent; Z is (CR 12 R 13 ) m and; each R is independently selected from the group consisting of halogen, deuterium, hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium; p is 0, 1, 2, 3 or 4; R aand R b are each independently H or unsubstituted C1-C3 alkyl; When Y is absent, m is 2, 3, 4, or 5; or Y is NR 10 or when O, m is 1, 2, 3 or 4; and in addition: R1, R2, R4 and R5 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; or alternatively, R2 and R5 together with the carbon atom to which they are attached form a single bond; R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R3 and R1 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; or alternatively, R3 and R4 together with the carbon atom to which they are attached form a C3-C5 cycloalkyl; R6, R7, R8, R9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen and deuterium; R 10 is selected from the group consisting of H, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens; Each R 12 and R 13 is independently selected from the group consisting of H, halogen, deuterium, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with hydroxyl or one or more halogens; R 14 , R 15 and R 16 are each independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens; Each R 17 and R 18 is independently selected from the group consisting of H, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogens.

[0093] In one embodiment of Formula (II), n is 1. In another embodiment of Formula (II), n is 2. In another embodiment of Formula (II), n is 3.

[0094] In another embodiment of formula (II), ring A is phenyl. In another embodiment of formula (II), ring A is pyridinyl. In another embodiment of formula (II), ring A is pyridazinyl. In another embodiment of formula (II), ring A is pyrimidinyl. In another embodiment of formula (II), ring A is pyrazinyl. In another embodiment of formula (II), ring A is triazinyl.

[0095] In another embodiment of formula (II), Y is NR 10 In another embodiment of formula (II), Y is O. In another embodiment of formula (II), Y is absent. In another embodiment of formula (II), ring A is phenyl and Y is NR 10 In another embodiment of formula (II), ring A is phenyl and Y is O. In another embodiment of formula (II), ring A is phenyl and Y is absent. In another embodiment of formula (II), ring A is pyridinyl and Y is NR 10 In another embodiment of formula (II), ring A is pyridinyl and Y is O. In another embodiment of formula (II), ring A is pyridinyl and Y is absent. In another embodiment of formula (II), ring A is pyridazinyl and Y is NR 10 In another embodiment of formula (II), ring A is pyridazinyl and Y is O. In another embodiment of formula (II), ring A is pyridazinyl and Y is absent. In another embodiment of formula (II), ring A is pyrimidinyl and Y is NR 10 In another embodiment of formula (II), ring A is pyrimidinyl and Y is O. In another embodiment of formula (II), ring A is pyrimidinyl and Y is absent. In another embodiment of formula (II), ring A is pyrazinyl and Y is NR 10In another embodiment of formula (II), ring A is pyrazinyl and Y is O. In another embodiment of formula (II), ring A is pyrazinyl and Y is absent. In another embodiment of formula (II), ring A is triazinyl and Y is NR 10 In another embodiment of formula (II), ring A is triazinyl and Y is O. In another embodiment of formula (II), ring A is triazinyl and Y is absent.

[0096] In another embodiment of formula (II), T is CR1R2. In another embodiment of formula (II), T is O. In another embodiment of formula (II), W is CR4R5. In another embodiment of formula (II), W is O. In another embodiment of formula (II), T is CR1R2 and W is CR4R5. In another embodiment of formula (II), T is O and W is CR4R5. In another embodiment of formula (II), T is CR1R2 and W is O.

[0097] In another embodiment of formula (II), V is CR3. In another embodiment of formula (II), V is N.

[0098] In another embodiment of formula (II), T is CR1R2 and V is CR3. In another embodiment of formula (II), T is O and V is CR3. In another embodiment of formula (II), T is CR1R2 and V is N. In another embodiment of formula (II), T is O and V is N.

[0099] In another embodiment of formula (II), W is CR4R5 and V is CR3. In another embodiment of formula (II), W is O and V is CR3. In another embodiment of formula (II), W is CR4R5 and V is N. In another embodiment of formula (II), W is O and V is N.

[0100] In another embodiment of formula (II), T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (II), T is CR1R2, W is O, and V is CR3. In another embodiment of formula (II), T is CR1R2, W is CR4R5, and V is N. In another embodiment of formula (II), T is CR1R2, W is O, and V is N. In another embodiment of formula (II), T is O, W is CR4R5, and V is CR3.

[0101] In another embodiment of formula (II), E is NR a R b In another embodiment of formula (II), E is C(=O)NR a R b In another embodiment of formula (II), E is C1-C3 alkylene-NR a R bIn another embodiment of formula (II), E is unsubstituted C1-C3 alkyl, unsubstituted C2-C4 alkenyl, or unsubstituted C2-C4 alkynyl. In another embodiment of formula (II), E is C1-C3 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of formula (II), E is unsubstituted C1-C3 alkyl. In another embodiment of formula (II), E is C1-C3 alkyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of formula (II), E is unsubstituted C3-C8 cycloalkyl. In another embodiment of formula (II), E is C3-C8 cycloalkyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of formula (II), E is unsubstituted C1-C3 alkylene-(C3-C8 cycloalkyl). In another embodiment of formula (II), E is C1-C3 alkylene-(C3-C8 cycloalkyl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is unsubstituted 4-10 membered heterocyclyl. In another embodiment of formula (II), E is 4-10 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is unsubstituted C1-C3 alkylene-(4-10 membered heterocyclyl). In another embodiment of formula (II), E is a C1-C3 alkylene-(4-10 membered heterocyclyl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is an unsubstituted C6-C 10 In another embodiment of formula (II), E is a C6-C aryl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. 10 In another embodiment of formula (II), E is an unsubstituted C1-C3 alkylene-(C6-C 10In another embodiment of formula (II), E is C1-C3 alkylene-(C6-C aryl) substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. 10 In another embodiment of formula (II), E is an unsubstituted 5-10 membered heteroaryl. In another embodiment of formula (II), E is a 5-10 membered heteroaryl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0102] In another embodiment of formula (II), E is an unsubstituted 4-7 membered heterocyclyl. In another embodiment of formula (II), E is a 4-7 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is an unsubstituted 4-6 membered heterocyclyl. In another embodiment of formula (II), E is a 4-6 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is an unsubstituted 4-membered heterocyclyl. In another embodiment of formula (II), E is a 4 membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is an unsubstituted 5-membered heterocyclyl. In another embodiment of formula (II), E is a 5-membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is an unsubstituted 6-membered heterocyclyl. In another embodiment of formula (II), E is a 6-membered heterocyclyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0103] In another embodiment of formula (II), E is NR a R b , C(=O)NR a R b , C1-C3 alkylene-NR a R b, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkylene-NR a R b , C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0104] In another embodiment of formula (II), E is C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0105] In another embodiment of formula (II), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 aryl), where C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl, C1-C3 alkylene-(4-10 membered heterocyclyl), C6-C 10 Aryl or C1-C3 alkylene-(C6-C 10 Aryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl.

[0106] In another embodiment of formula (II), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl or C1-C3 alkylene-(4-10 membered heterocyclyl), where C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4-10 membered heterocyclyl or C1-C3 alkylene-(4-10 membered heterocyclyl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0107] In another embodiment of formula (II), E is C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl), wherein C1-C3 alkyl, C3-C8 cycloalkyl or C1-C3 alkylene-(C3-C8 cycloalkyl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0108] In another embodiment of formula (II), E is methyl, wherein methyl is unsubstituted or substituted with one or more halogens, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is methyl. In another embodiment of formula (II), E is trifluoromethyl. In another embodiment of formula (II), E is dioxanyl, wherein dioxanyl is unsubstituted or substituted with one or more halogens, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is tetrahydropyranyl, wherein tetrahydropyranyl is unsubstituted or substituted with one or more halogens, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is tetrahydrofuranyl, wherein tetrahydrofuranyl is unsubstituted or substituted with one or more halogens, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is azetidinyl, where azetidinyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is oxetanyl, where oxetanyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl. In another embodiment of formula (II), E is morpholinyl, where morpholinyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

[0109] In another embodiment of formula (II), R 14 is H. In another embodiment of formula (II), R 14 is unsubstituted C1-C3 alkyl. In another embodiment of formula (II), R 15 and R 16 are each H. In another embodiment of formula (II), R 15 is unsubstituted C1-C3 alkyl, R 16 is H. In another embodiment of formula (II), R 16is unsubstituted C1-C3 alkyl, R 15 is H. In another embodiment of formula (II), each R 17 and R 18 is H. In another embodiment of formula (II), R 17 is unsubstituted C1-C3 alkyl, R 18 is H. In another embodiment of formula (II), R 18 is unsubstituted C1-C3 alkyl, R 17 is H. In another embodiment of formula (II), R 14 , R 15 , R 16 , R 17 and R 18 is an unsubstituted C1-C3 alkyl and the others are each H.

[0110] In another embodiment of formula (II), m is 1. In another embodiment of formula (II), m is 2. In another embodiment of formula (II), m is 3. In another embodiment of formula (II), m is 4. In another embodiment of formula (II), m is 5. In another embodiment of formula (II), m is 1, 2 or 3. In another embodiment of formula (II), m is 2, 3 or 4. In another embodiment of formula (II), m is 1 or 2. In another embodiment of formula (II), m is 3 or 4.

[0111] In another embodiment of formula (II), Y is O and m is 1. In another embodiment of formula (II), Y is O and m is 2. In another embodiment of formula (II), Y is O and m is 3. In another embodiment of formula (II), Y is O and m is 4. In another embodiment of formula (II), Y is O and m is 1, 2 or 3. In another embodiment of formula (II), Y is O and m is 2, 3 or 4. In another embodiment of formula (II), Y is O and m is 1 or 2. In another embodiment of formula (II), Y is O and m is 3 or 4.

[0112] In another embodiment of formula (II), Y is absent and m is 1. In another embodiment of formula (II), Y is absent and m is 2. In another embodiment of formula (II), Y is absent and m is 3. In another embodiment of formula (II), Y is absent and m is 4. In another embodiment of formula (II), Y is absent and m is 1, 2 or 3. In another embodiment of formula (II), Y is absent and m is 2, 3 or 4. In another embodiment of formula (II), Y is absent and m is 1 or 2. In another embodiment of formula (II), Y is absent and m is 3 or 4.

[0113] In another embodiment of formula (II), Y is NR 10 and m is 1. In another embodiment of formula (II), Y is NR 10 and m is 2. In another embodiment of formula (II), Y is NR 10 and m is 3. In another embodiment of formula (II), Y is NR 10 and m is 4. In another embodiment of formula (II), Y is NR 10 and m is 1, 2 or 3. In another embodiment of formula (II), Y is NR 10 and m is 2, 3 or 4. In another embodiment of formula (II), Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), Y is NR 10 and m is 3 or 4.

[0114] In another embodiment of formula (II), ring A is phenyl and n is 1. In another embodiment of formula (II), ring A is phenyl and n is 2. In another embodiment of formula (II), ring A is phenyl and n is 3. In another embodiment of formula (II), ring A is pyridinyl and n is 1. In another embodiment of formula (II), ring A is pyridinyl and n is 2. In another embodiment of formula (II), ring A is pyridinyl and n is 3. In another embodiment of formula (II), ring A is pyridazinyl and n is 1. In another embodiment of formula (II), ring A is pyridazinyl and n is 2. In another embodiment of formula (II), ring A is pyridazinyl and n is 3. In another embodiment of formula (II), ring A is pyrimidinyl and n is 1. In another embodiment of formula (II), ring A is pyrimidinyl and n is 2. In another embodiment of formula (II), ring A is pyrimidinyl and n is 3. In another embodiment of formula (II), ring A is pyrazinyl and n is 1. In another embodiment of formula (II), ring A is pyrazinyl and n is 2. In another embodiment of formula (II), ring A is pyrazinyl and n is 3. In another embodiment of formula (II), ring A is triazinyl and n is 1. In another embodiment of formula (II), ring A is triazinyl and n is 2. In another embodiment of formula (II), ring A is triazinyl and n is 3.

[0115] In another embodiment of formula (II), ring A is phenyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is phenyl, n is 2 and Y is NR 10 In another embodiment of formula (II), ring A is phenyl, n is 3 and Y is NR 10In another embodiment of formula (II), ring A is phenyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is phenyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is phenyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is phenyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is phenyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is phenyl, n is 3, and Y is absent.

[0116] In another embodiment of formula (II), ring A is phenyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 3 and Y is NR 10and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, n is 3, Y is absent, and m is 3 or 4.

[0117] In another embodiment of formula (II), ring A is pyridinyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is pyridinyl, n is 2 and Y is NR 10 In another embodiment of formula (II), ring A is pyridinyl, n is 3 and Y is NR 10 In another embodiment of formula (II), ring A is pyridinyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is pyridinyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is pyridinyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is pyridinyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is pyridinyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is pyridinyl, n is 3, and Y is absent.

[0118] In another embodiment of formula (II), ring A is pyridinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 3 and Y is NR10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridinyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridinyl, n is 3, Y is absent, and m is 3 or 4.

[0119] In another embodiment of formula (II), ring A is pyridazinyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is pyridazinyl, n is 2 and Y is NR10 In another embodiment of formula (II), ring A is pyridazinyl, n is 3 and Y is NR 10 In another embodiment of formula (II), ring A is pyridazinyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is pyridazinyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, and Y is absent.

[0120] In another embodiment of formula (II), ring A is pyridazinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyridazinyl, n is 1 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 2 and Y is NR10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4.

[0121] In another embodiment of formula (II), ring A is pyrimidinyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is pyrimidinyl, n is 2 and Y is NR 10 In another embodiment of formula (II), ring A is pyrimidinyl, n is 3 and Y is NR 10 In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, and Y is absent.

[0122] In another embodiment of formula (II), ring A is pyrimidinyl, n is 1 and Y is NR 10and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4.

[0123] In another embodiment of formula (II), ring A is pyrazinyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is pyrazinyl, n is 2 and Y is NR 10 In another embodiment of formula (II), ring A is pyrazinyl, n is 3 and Y is NR 10 In another embodiment of formula (II), ring A is pyrazinyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, and Y is absent.

[0124] In another embodiment of formula (II), ring A is pyrazinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 3 and Y is NR 10and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 2 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.

[0125] In another embodiment of formula (II), ring A is triazinyl, n is 1 and Y is NR 10 In another embodiment of formula (II), ring A is triazinyl, n is 2 and Y is NR 10In another embodiment of formula (II), ring A is triazinyl, n is 3 and Y is NR 10 In another embodiment of formula (II), ring A is triazinyl, n is 1, and Y is O. In another embodiment of formula (II), ring A is triazinyl, n is 2, and Y is O. In another embodiment of formula (II), ring A is triazinyl, n is 3, and Y is O. In another embodiment of formula (II), ring A is triazinyl, n is 1, and Y is absent. In another embodiment of formula (II), ring A is triazinyl, n is 2, and Y is absent. In another embodiment of formula (II), ring A is triazinyl, n is 3, and Y is absent.

[0126] In another embodiment of formula (II), ring A is triazinyl, n is 1 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 2 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 3 and Y is NR 10 and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 3, Y is absent, and m is 1 or 2. In another embodiment of formula (II), ring A is triazinyl, n is 1, and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 2 and Y is NR 10and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 3 and Y is NR 10 and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of formula (II), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4.

[0127] In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, and V is CR3. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 1. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 3. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 1. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 3.

[0128] In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and Y is O. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and Y is O. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.

[0129] In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.In another embodiment of formula (II), ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4. In another embodiment of formula (II), ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4. In another embodiment of formula (II), p is 0, and R1, R2, R4 and R5 are each H. In another embodiment of formula (II), p is 0; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (II), p is 0; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R. 11 In another embodiment of formula (II), p is 0; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are H and R 12 and R 13 are H, respectively.

[0130] In another embodiment of formula (II), p is 1 and R1, R2, R4 and R5 are each H. In another embodiment of formula (II), p is 1; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (II), p is 1; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 In another embodiment of formula (II), p is 1; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are H and R12 and R 13 are H, respectively.

[0131] In another embodiment of formula (II), p is 2 and R1, R2, R4 and R5 are each H. In another embodiment of formula (II), p is 2; R1, R2, R4 and R5 are each H; R3 is H. In another embodiment of formula (II), p is 2; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 In another embodiment of formula (II), p is 2; R1, R2, R4 and R5 are each H; R3 is H; R6, R7, R8, R9 and R 11 are H and R 12 and R 13 are H, respectively.

[0132] In another embodiment of formula (II), p is 1, 2, 3 or 4 and R is fluorine. In another embodiment of formula (II), p is 1, 2, 3 or 4 and R is deuterium. In another embodiment of formula (II), p is 1, 2, 3 or 4 and each R is independently selected from the group consisting of hydroxyl, cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium. In another embodiment of formula (II), p is 1, 2, 3 or 4 and each R is independently selected from the group consisting of cyano, unsubstituted C1-C3 alkyl, and C1-C3 alkyl substituted with one or more halogens or deuterium. In another embodiment of formula (II), p is 1 and R is unsubstituted C1-C3 alkyl. In another embodiment of formula (II), p is 1 and R is methyl. In another embodiment of formula (II), p is 1 or 2 and each R is methyl. In another embodiment of formula (II), p is 1 and R is C1-C3 alkyl substituted with one or more halogens. In another embodiment of formula (II), p is 1 and R is CF3. In another embodiment of formula (II), p is 1 or 2 and each R is CF3.

[0133] In another embodiment of formula (II), one or more of R1, R2, R4, and R5 are fluorine. In another embodiment of formula (II), one or more of R1, R2, R4, and R5 are deuterium. In another embodiment of formula (II), R6, R7, R8, R9, and R 11 In another embodiment of formula (II), one or more of R, R, R, R and R 11 In another embodiment of formula (II), one or more of R 12 and R 13 In another embodiment of formula (II), one or more of R 12 and R 13 One or more of is deuterium.

[0134] In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 is H. In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 is H and m is 2. In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 14 , R 15 , R 16 , R 17 and R 18 is H. In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 14 , R 15 , R 16 , R 17 and R 18 is H and m is 2. In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17and R 18 is H. In another embodiment of formula (II), Y is O, T is CR1R2, V is CR3, W is CR4R5, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 Each of is H and m is 2.

[0135] Each of the embodiments described herein with respect to compounds of formula II also applies to compounds of formula II-A.

[0136] According to formula IA, I, II-A or II herein, when ring A is pyridinyl, the position of the pyridinyl N atom is specified as shown below: [ka] .

[0137] Further, according to formula IA, I, II-A or II herein, when ring A is pyridazinyl, the position of the pyridazinyl N atom is specified as shown below: [ka] .

[0138] Further, according to formula IA, I, II-A or II herein, when ring A is pyrimidinyl, the position of the pyrimidinyl N atom is specified as shown below: [ka] .

[0139] Further, according to formula IA, I, II-A or II herein, when ring A is pyrazinyl, the position of the pyrazinyl N atom is specified as shown below: [ka] .

[0140] Further, according to formula IA, I, II-A or II herein, when ring A is triazinyl, the position of the triazinyl N atom is specified as shown below: [ka] All other variables described in formula IA, I, II-A or II are as defined above.

[0141] Particular embodiments of the compounds of formula IA, I, II-A, II, or a pharma- ceutically acceptable salt thereof, are set forth below in Table 1. The compounds of formula IA, I, II-A, II, or a pharma- ceutically acceptable salt thereof, and the compounds of Table 1, or a pharma- ceutically acceptable salt thereof, are often referred to herein, collectively or individually, as "compounds of the invention" or "compounds provided herein." [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9]

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

[0142] The disclosed compounds have one or more stereocenters, and each stereocenter can be independently in either R or S conformation.In one embodiment, the compounds described herein are optically active or exist in racemic form.It is understood that the compounds described herein include racemic, optically active, positional isomers and stereoisomeric forms, or combinations thereof that have the therapeutically useful properties described herein.

[0143] The preparation of optically active forms is accomplished in any suitable manner, such as, for example, by resolution of racemic forms by recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using chiral stationary phases, as non-limiting examples. In one embodiment, a mixture of two or more isomers is used as the disclosed compounds described herein. In another embodiment, a pure isomer is used as the disclosed compounds described herein. In another embodiment, the compounds described herein contain one or more chiral centers. These compounds are prepared by any means, such as stereoselective synthesis, enantioselective synthesis, or separation of mixtures of enantiomers or diastereomers. The resolution of the compounds and their isomers is accomplished by any means, such as, for example, by chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography, as non-limiting examples.

[0144] In one embodiment, the disclosed compounds may exist as tautomers, and all tautomers are included within the scope of the compounds presented herein.

[0145] The compounds described herein also include isotopically labeled compounds in which one or more atoms are replaced with an atom having the same atomic number but an atomic mass or mass number different from that normally found in nature. Examples of isotopes suitable for inclusion in the compounds described herein include: 2 H, 3 H, 11 C. 13 C. 14 C. 36 Cl, 18 F, 123I, 125 I, 13 N, 15 N, 15 O. 17 O. 18 O. 32 P and 35 In one embodiment, isotopically labeled compounds are useful in tissue distribution studies of drugs or substrates. In another embodiment, substitution with heavier isomers such as deuterium provides greater metabolic stability (e.g., increased in vivo half-life or reduced administration requirements). In another embodiment, the compounds described herein are 2 Contains the H (i.e. deuterium) isotope.

[0146] In yet another embodiment, 11 C. 18 F, 15 O and 13 Substitution with positron emitting isotopes, such as N, is useful in positron emission tomography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds are prepared by any suitable method or process that employs a suitable isotopically labeled reagent in place of a non-labeled reagent that would otherwise be used.

[0147] The specific compounds described herein, as well as other compounds encompassed by one or more of the formulas described herein having different substituents, can be prepared using the techniques and materials described herein, for example in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989); March, Advanced Organic Chemistry 4 th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001) and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999), all of which are incorporated by reference for such disclosures. The general methods for the preparation of the compounds described herein are modified using appropriate reagents and conditions for the introduction of the various moieties found in the formulas provided herein.

[0148] The compounds described herein are synthesized using any suitable procedure beginning with compounds available from commercial sources or prepared using the procedures described herein.

[0149] Treatment method The compounds of the present invention can be used in a method for treating a disease or condition in a subject, the method comprising administering to the subject a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention. In one embodiment of the method described herein, the subject is a human. In one aspect, the compounds provided herein are useful for treating a disease or condition by acting as an agonist of the orexin-2 receptor.

[0150] The compounds of the present invention may be used to treat a disease or condition selected from the group consisting of narcolepsy, cataplexy or hypersomnia in a subject in need of such treatment.

[0151] In one embodiment, the compounds of the present invention can be used to treat narcolepsy in a subject. In one embodiment, the compounds of the present invention can be used to treat cataplexy in a subject. In one embodiment, the compounds of the present invention can be used to treat hypersomnia in a subject.

[0152] Orexin-2 receptor is important in a wide range of biological functions.This suggests that Orexin-2 receptor plays a role in various disease processes in humans or other species.The compounds of the present invention are useful for treating, preventing or ameliorating the risk of one or more of the following symptoms or diseases of various neurological and psychiatric diseases related to changes in sleep / wake function: i.e., narcolepsy, narcolepsy with cataplexy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndromes characterized by hypersomnia (e.g., in subjects with Kleine-Lewin syndrome, major depression with hypersomnia, dementia with Lewy bodies, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoarousal syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, multiple system atrophy, acute disseminated encephalomyelitis, Guillain-Barré syndrome, Rasmussen's encephalitis, Wernicke's encephalitis, limbic encephalitis, or Hashimoto's encephalopathy), coma, loss of consciousness, obesity (e.g., malignant mastocytosis, exogenous obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hypopituitary hyseal obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, syndromic obesity, infantile obesity, upper body obesity, dietary obesity, hypogonadotropic obesity, systemic mastocytosis, simple or central obesity), insulin resistance syndrome, Alzheimer's disease, disturbances of consciousness such as coma, side effects and complications due to anesthesia, sleep disturbances, excessive daytime sleepiness, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, REM sleep interruptions, jet lag, jet lag syndrome, shift worker sleep disorder, sleep disorders, night terrors, depression, major depression, sleepwalking, enuresis, sleep disorders, Alzheimer's evening dusk), sundowning phenomenon, disorders related to circadian rhythm, fibromyalgia, conditions resulting from poor quality sleep, overeating, compulsive eating disorder, obesity-related disorders, hypertension, diabetes, increased plasma insulin concentration and insulin resistance, hyperlipidemia, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colorectal cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease,Sexual and reproductive dysfunction such as abnormal heartbeat, arrhythmias, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disorders, polycystic ovarian disease, craniopharingioma, Prader-Willi syndrome, Froelich syndrome, growth hormone deficiency, normal mutant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, Syndrome X, reproductive hormone abnormalities, reduced fertility, infertility, male hypogonadism, female hirsutism, fetal defects associated with obesity in pregnant women, gastrointestinal motility disorders such as obesity-related gastroesophageal reflux, obesity hypometabolism Pickwickian syndrome, respiratory diseases such as dyspnea, inflammation such as systemic inflammation of the vascular system, arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain, gallbladder disease, gout, kidney cancer, risk of secondary consequences of obesity such as reduced risk of left ventricular hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, autoimmune encephalitis, cancer-related fatigue (e.g. excessive daytime sleepiness or fatigue associated with cancer and / or chemotherapy), cancer-related nausea and vomiting, corticobasal degeneration, Huntington's disease, neuromyelitis optica, nociception, progressive supranuclear palsy, integration Schizophrenia, systemic lupus erythematosus, traumatic brain injury, hot flushes, night sweats, diseases of the reproductive / urinary system, diseases related to sexual function or fertility, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attacks, panic disorder, post-traumatic stress disorder (PTSD), separation anxiety disorder, social phobia, anxiety disorders, acute neurological and psychiatric disorders such as brain defects after cardiac bypass surgery and transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord injury, head trauma, perinatal hypoxia, cardiac arrest, hypo Blood sugar nerve damage, Huntington's chorea, amyotrophic lateral sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasms, tremors, epilepsy, disorders related to muscle spasms, delirium, amnesic disorders, age-related cognitive decline, schizoaffective disorder, delusional disorders, drug addiction, movement disorders, chronic fatigue syndrome, fatigue, medication-induced tremor-paresis syndrome, Gilles de la Tourette's syndrome, chorea, myoclonus, tics, restless legs syndrome, dystonia, movement disorders, attention deficit hyperactivity disorder (ADHD), behavioral disorders, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain,Joint pain, toothache, cataplexy, and traumatic brain injury (TBI).

[0153] In particular, the compounds of the present invention are useful as therapeutic or prophylactic agents for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndromes characterized by excessive sleepiness (e.g., in Parkinson's disease, Guillain-Barre syndrome or Kleine-Lewin syndrome), Alzheimer's disease, obesity, insulin resistance syndrome, heart failure, diseases associated with bone loss, sepsis, disturbances of consciousness such as coma, side effects and complications due to anesthesia, etc., or as anesthetic antagonists.

[0154] In one embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as prophylactic or therapeutic agents for narcolepsy.

[0155] In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for narcolepsy type 1. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for narcolepsy type 2. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for narcolepsy and excessive daytime sleepiness. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for narcolepsy, cataplexy, and excessive daytime sleepiness. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for narcolepsy and cataplexy. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for excessive daytime sleepiness. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for idiopathic hypersomnia. In another embodiment, the compounds of the present invention are useful as prophylactic or therapeutic agents for obstructive sleep apnea.

[0156] In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as prophylactic or therapeutic agents for hypersomnia in Parkinson's disease.

[0157] In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as prophylactic or therapeutic agents for hypersomnia.In another embodiment, the compounds of the present invention have orexin-2 receptor agonist activity and are useful as prophylactic or therapeutic agents for excessive daytime sleepiness associated with Parkinson's disease.

[0158] In another embodiment, the compounds of the invention have orexin-2 receptor agonist activity and are useful as prophylactic or therapeutic agents for excessive daytime sleepiness or fatigue associated with cancer and / or chemotherapy.

[0159] In another embodiment, the present invention provides a method of treating narcolepsy in a subject in need of such treatment, comprising administering to the subject a compound of formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0160] In another embodiment, the present invention provides a method of treating narcolepsy type 1 in a subject in need of such treatment, comprising administering to the subject a compound of formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0161] In another embodiment, the present invention provides a method of treating narcolepsy type 2 in a subject in need of such treatment, comprising administering to the subject a compound of formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0162] In another embodiment, the present invention provides a method of treating narcolepsy and excessive daytime sleepiness in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0163] In another embodiment, the present invention provides a method of treating narcolepsy, cataplexy, and excessive daytime sleepiness in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0164] In another embodiment, the present invention provides a method of treating narcolepsy and cataplexy in a subject in need of such treatment, comprising administering to the subject a compound of formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0165] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0166] In another aspect, the present invention provides a method of treating idiopathic hypersomnia in a subject in need of such treatment, comprising administering to the subject a compound of formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0167] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and idiopathic hypersomnia in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0168] In another aspect, the present invention provides a method of treating obstructive sleep apnea in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0169] In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and obstructive sleep apnea in a subject in need of such treatment, comprising administering to the subject a compound of Formula IA, I, II-A or II, or a pharma- ceutically acceptable salt thereof.

[0170] In any of the methods described herein, the subject is administered a compound of formula I. In any of the methods described herein, the subject is administered a compound of formula II.

[0171] Each of the embodiments described herein with respect to the use of compounds of formula I also applies to compounds of formula IA. Each of the embodiments described herein with respect to the use of compounds of formula II also applies to compounds of formula II-A.

[0172] In any of the compositions or methods described herein, the compound of formula IA, I, II-A, II, or a pharma- ceutically acceptable salt thereof is present and / or administered in a therapeutically effective amount.

[0173] Administration / Dosage / Formulation In another aspect, provided herein is a pharmaceutical composition comprising at least one compound of the present invention in association with a pharma- ceutically acceptable carrier.

[0174] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied to obtain an amount of the active ingredient effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration without being toxic to the patient.

[0175] In particular, the selected dose level will depend on a variety of factors such as the activity of the particular compound used, the time of administration, the rate of excretion of the compound, the duration of treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and previous medical history of the patient being treated, and similar factors known in the medical arts.

[0176] A medical practitioner, such as a physician or veterinarian, having ordinary skill in the art can easily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian can begin administering the pharmaceutical composition to administer the disclosed compounds at levels lower than required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0177] In certain embodiments, it is particularly advantageous to formulate the compound in unit dosage form for ease of administration and uniformity of dosage.As used herein, unit dosage form refers to a physically separate unit adapted as a unit dosage for the patient to be treated; each unit contains a predetermined amount of the disclosed compound calculated to produce a desired therapeutic effect in association with the required pharmaceutical vehicle.The unit dosage form of the present invention is determined by and directly depends on (a) the specific characteristics of the disclosed compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the field of compounding / formulating such disclosed compound for treating narcolepsy or cataplexy in patients.

[0178] In one embodiment, the compounds of the present invention are formulated using one or more pharma- ceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions of the present invention comprise a therapeutically effective amount of the disclosed compounds and a pharma- ceutically acceptable carrier.

[0179] In some embodiments, the dosage of the disclosed compound is about 1 mg to about 1,000 mg. In some embodiments, the dosage of the disclosed compound used in the compositions described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 20 mg, or less than about 10 mg. For example, the dosage is about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 260 mg, 280 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or about 600 mg.

[0180] The administration route of any of the compositions of the present invention includes oral, nasal, rectal, vaginal, parenteral, buccal, sublingual or topical.The compound for use in the present invention can be formulated for administration by any suitable route, such as oral or parenteral, for example transdermal, transmucosal (e.g. sublingual, lingual, (trans)buccal, (trans)urethral, ​​vaginal (e.g. vaginal and perivaginal), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalation and topical administration.In one embodiment, the preferred administration route is oral.

[0181] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gelcaps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions useful in the present invention are not limited to the specific formulations and compositions described herein.

[0182] For oral application, tablets, dragees, liquids, drops, suppositories or capsules, caplets and gelcaps are particularly suitable. The composition intended for oral use can be prepared according to any method known in the art, and such compositions can contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutical excipients suitable for the manufacture of tablets. Such excipients include, for example, inert diluents, such as lactose; granulating and disintegrating agents, such as corn starch; binding agents, such as starch; and lubricants, such as magnesium stearate. Tablets can be uncoated or can be coated by known techniques for scientific precision or to delay the release of active ingredients. Preparations for oral use can also be presented as hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.

[0183] For parenteral administration, the disclosed compounds can be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus or continuous infusion. Suspensions, solutions or emulsions in oily or aqueous vehicles, optionally containing other formulating agents such as suspending, stabilizing or dispersing agents, can be used.

[0184] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims and examples described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the claims appended hereto. For example, modifications using no more than routine experimentation with art-recognized variations in reaction conditions, including but not limited to reaction times, reaction sizes / volumes and experimental reagents, such as solvents, catalysts, pressure, atmospheric conditions, such as nitrogen atmosphere, and reducing / oxidizing agents, should be understood to be within the scope of this application.

[0185] Whenever values ​​and ranges are provided herein, it is understood that all values ​​and ranges subsumed within those values ​​and ranges are intended to be encompassed within the scope of the invention. Moreover, all values ​​subsumed within those ranges, as well as the upper or lower limits of a range of values, are also contemplated by this application.

[0186] The following examples further illustrate aspects of the present invention, but are not in any way a limitation of the teachings or disclosure of the invention described herein. EXAMPLES

[0187] Working Example The present invention is further illustrated by the following examples, which should not be construed as further limiting. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of organic synthesis, cell biology, cell culture, molecular biology, transgenic biology, microbiology and immunology, which are within the skill of the art.

[0188] General Procedure Example 1: Synthesis Procedure The synthetic procedures for preparing the compounds of the present invention are readily available to those skilled in the art.Unless otherwise indicated, starting materials are generally obtained from commercial suppliers.Synthetic procedures for other macrocyclic compounds can be found, for example, in US Application No. 17 / 104,993 and PCT Application No. PCT / US20 / 62320, both of which were filed on November 25, 2020 and are expressly incorporated herein by reference.

[0189] The following abbreviations may be used in the synthetic examples below: AcOH = acetic acid DCM = dichloromethane MsCl = methanesulfonyl chloride MeOH = methanol THF = tetrahydrofuran EtOH = ethanol PtO2 = platinum dioxide HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate DIPEA or DIEA = N,N-diisopropylethylamine t Bu = tert-butyl MeCN = acetonitrile PE=petroleum ether EtOAc = ethyl acetate DMF = Dimethylformamide TFA = trifluoroacetic acid LiOH = lithium hydroxide min=minutes hr=hour NaH = sodium hydride Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(O) DMSO = dimethyl sulfoxide i-PrOH = isopropanol Pd / C = palladium on carbon XantPhos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene Boc = tert-butyloxycarbonyl Ms = methanesulfonyl Bn=benzyl Et = ethyl Cbz = carboxybenzyl PMB = para-methoxybenzyl DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene NBS = N-bromosuccinimide Pd(dppf)Cl2 = [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) DMAP = 4-(dimethylamino)pyridine NCS = N-chlorosuccinimide DMPU = 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone LDA = lithium diisopropylamide HOBt = 1-hydroxybenzotriazole EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

[0190] Scheme 1 [ka]

[0191] Example 1.1 [ka] A 5 L 4-neck round bottom flask maintained under an inert purged atmosphere of nitrogen was charged with 4-[2-(benzyloxy)phenyl]cyclohexan-1-one (210 g, 0.75 mol, 1.0 equiv.) in tetrahydrofuran (2.1 L). To this was added L-selectride (1 mol / L in THF) (1123 mL, 1.5 equiv.) dropwise with stirring at 0° C. The resulting solution was stirred at room temperature for 4 hr. The reaction was then quenched by the addition of water / ice. The resulting solution was extracted with ethyl acetate and the organic phase was washed with brine. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography to give 137 g (64%) of (1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexan-1-ol as a solid. 1 H NMR (400MHz, CDCl3): δ 7.45 - 7.26 (6H, m), 7.16 (1H, dd), 6.98- 6.90 (2H, m), 5.09 (2H, s), 4.13 (1H, s), 3.12- 3.02 (1H, m), 1.93 - 1.82 (4H, m), 1.73 - 1.41 (4H, m).

[0192] [ka] A 2 L 4-neck round bottom flask maintained under an inert purged atmosphere of nitrogen was charged with NaH (60% wt, 26.9 g, 2.0 equiv) in tetrahydrofuran (200 mL). To this was added dropwise with stirring a solution of (1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexan-1-ol (95.0 g, 336 mmol, 1.0 equiv) in THF (200 mL). After stirring for 2 hr, a solution of 3-bromo-2-(bromomethyl)pyridine (143.5 g, 571 mmol, 1.70 equiv) in THF (550 mL) was added dropwise at 50-55 °C. The resulting solution was stirred at 50-55 °C for 14 hr. The reaction mixture was cooled. Water was then added to quench the reaction. The resulting solution was extracted with ethyl acetate and the combined organic layers were dried over anhydrous sodium sulfate. The solid was filtered off. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography to give 94.0 g (62%) of 3-bromo-2-([[(1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexyl]oxy]methyl)pyridine as a solid. 1 H NMR (400MHz, CDCl3): δ 8.57 (1H, d), 7.90 (1H, dd), 7.48 - 7.26 (6H, m), 7.18 - 7.14 (2H, m), 6.98 - 6.91 (2H, m), 5.12 (2H, s), 4.77 (2H, s), 3.86 (1H, s), 3.17 - 3.10 (1H, m), 2.20 - 2.15 (2H, m), 1.98 - 1.88 (2H, m), 1.69 - 1.57 (4H, m).

[0193] [ka] A 2 L 4-neck round bottom flask maintained under an inert purged atmosphere of nitrogen was charged with Xantphos (10.7 g, 18.0 mmol, 0.10 equiv), Cs2CO3 (84 g, 258 mmol, 1.4 equiv), 3-bromo-2-([[(1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexyl]oxy]methyl)pyridine (84 g, 185 mmol, 1.0 equiv), Pd2(dba)3 (8.5 g, 9.0 mmol, 0.05 equiv) and tert-butyl carbamate (26 g, 222 mmol, 1.2 equiv) in 1,4-dioxane (840 mL). The resulting solution was stirred at 100 °C for 5 hr. The solids were removed by filtration. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography to give 74 g (82%) of tert-butyl N-[2-([[(1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexyl]oxy]methyl)pyridin-3-yl]carbamate as a solid.

[0194] [ka] A 2 L 3-neck round bottom flask was charged with tert-butyl N-[2-([[(1s,4s)-4-[2-(benzyloxy)phenyl]cyclohexyl]oxy]methyl)pyridin-3-yl]carbamate (74 g, 151 mmol, 1.0 equiv.) and Pd / C (7.4 g, 10% wt) in ethyl alcohol (740 mL), then hydrogen gas was bubbled into the resulting mixture. The resulting solution was stirred at room temperature for 14 hr. The solids were filtered off. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography to give 51.4 g (85%) of tert-butyl N-[2-([[(1s,4s)-4-(2-hydroxyphenyl)cyclohexyl]oxy]methyl)pyridin-3-yl]carbamate as a solid. LCMS (ESI): m / z [M+H] + = 399.1; 1H NMR (300MHz, CDCl3): δ 8.65(1H, s), 8.47 (1H, d), 8.19(1H, q), 7.26 - 7.21 (1H, m), 7.09 - 7.03 (1H, m), 6.92 - 6.86 (1H, m), 6.75(1H, q), 5.77 (1H, s), 4.84 (1H, s), 3.80 (1H, s), 2.94 - 2.93 (1H, m), 2.15 - 2.06 (2H, m), 1.88 - 1.47 (7H, m), 1.45 (9H, s), 1.26 (1H, d).

[0195] [ka] A 250 mL round bottom flask maintained under an inert purged atmosphere of nitrogen was charged with tert-butyl N-[2-([[(1s,4s)-4-(2-hydroxyphenyl)cyclohexyl]oxy]methyl)pyridin-3-yl]carbamate (8.0 g, 20.1 mmol, 1.0 equiv), K2CO3 (14.0 g, 100.4 mmol, 5.0 equiv), acetone (120 mL) and ethyl bromoacetate (5.03 g, 30.1 mmol, 1.5 equiv). The resulting solution was stirred at 50° C. for 24 hr. The solids were removed by filtration. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography to give ethyl 2-[2-[(1s,4s)-4-([3-[(tert-butoxycarbonyl)amino]pyridin-2-yl]methoxy)cyclohexyl]phenoxy]acetate (8.7 g, 89.4%) as an oil. LCMS (ESI): m / z [M+H] + = 485.

[0196] [ka] To a stirred mixture of ethyl 2-[2-[(1s,4s)-4-([3-[(tert-butoxycarbonyl)amino]pyridin-2-yl]methoxy)cyclohexyl]phenoxy]acetate (7.89 g, 16.3 mmol, 1.0 equiv) in MeOH (142 mL) and AcOH (15.8 mL) was added PtO2 (1.85 g, 8.14 mmol, 0.50 equiv) at room temperature under hydrogen atmosphere. The resulting mixture was stirred at room temperature under hydrogen atmosphere for 2 hr. The resulting mixture was filtered and the filter cake was concentrated under reduced pressure. The reaction was quenched with sat. NaHCO3 (aq.) at 0 °C. The resulting mixture was extracted with CH2Cl2 (3x500 mL). The combined organic layers were washed with brine (3x200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give a mixture of cis and trans diastereomers (7 g, 88.7%) as a solid. The crude product was purified by Prep-TLC to give a cis-racemic mixture of ethyl 2-(2-((1S,4s)-4-((3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohexyl)phenoxy)acetate (4.1 g) and a trans-racemic mixture (1.7 g). LCMS (ESI): m / z [M+H] + = 491.

[0197] [ka] A 500 mL round bottom flask maintained under a purged atmosphere of nitrogen was charged with the cis-racemic mixture of ethyl 2-(2-((1S,4s)-4-((3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohexyl)phenoxy)acetate (4.1 g, 8.4 mmol, 1.0 equiv), MeOH (30 mL), THF (60 mL), HO (30 mL) and lithium hydroxide (83 mg, 3.5 mmol, 5.0 equiv). The reaction was stirred at room temperature for 2 hr. The reaction was concentrated and the residue was purified by reverse phase chromatography to give 2-(2-((1s,4s)-4-((3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohexyl)phenoxy)acetic acid (2.35 g, 60.8%) as a solid. LCMS (ESI): m / z [M+H] + = 463.

[0198] [ka] To a 2000 mL round bottom flask was added 2-(2-((1s,4s)-4-((3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohexyl)phenoxy)acetic acid (100 mg, 0.216 mmol, 1.0 equiv), MeCN (36 mL), DMF (9 mL), HATU (124 mg, 0.326 mmol, 1.5 equiv) and DIPEA (56 mg, 0.436 mmol, 2.0 equiv) under nitrogen atmosphere. The resulting solution was stirred at room temperature for 3 hr. The resulting mixture was concentrated. The crude product tert-butyl((2 1 S,2 4 S,5 2 R,5 3 S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)carbamate was purified by column chromatography to give the product. LCMS (ESI): m / z [M+H] + = 445.

[0199] [ka] In a 500 mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, the crude mixture tert-butyl ((2 1 S,2 4 S,5 2 R,5 3 S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)carbamate (2 g, 4.50 mmol, 1.0 equiv), dichloromethane (120 mL), and TFA (40 mL) were added. The resulting solution was stirred at 25° C. for 1 hr. The resulting mixture was concentrated in vacuo. The crude product was purified by Prep-HPLC to give (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 -amino-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (800 mg, 51.6%) was obtained as a solid. LCMS (ESI): m / z [M+H] + = 345.

[0200] [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3To a solution of (S)-amino-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (70 mg, 0.20 mmol, 1.0 equiv.) and (S)-oxetane-2-carboxylic acid (62 mg, 0.61 mmol. 3.0 equiv.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (58 mg, 0.30 mmol, 1.5 equiv.) and HOBt (47 mg, 0.30 mmol, 1.5 equiv.) and DIEA (79 mg, 0.61 mmol, 3.0 equiv.) were added. The resulting mixture was stirred at 25° C. for 1 hr. The crude was purified by reverse flash chromatography to give (S)-N-((2 1 S,2 4 S,5 2 R,5 3 S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)oxetane-2-carboxamide (75 mg, 0.18 mmol, 86%) was obtained as a solid. LCMS (ESI): m / z [M+H] + = 429. 1 H NMR (400MHz, methanol-d4) δ 7.20 - 7.13 (m, 1H), 7.08 (dd, 1H), 6.91 - 6.83 (m, 2H), 5.34 (d, 1H), 5.29 - 5.23 (m, 1H), 5.08 (dd, 1H), 4.80 - 4.71 (m, 1H), 4.71 - 4.60 (m, 1H), 4.25 - 4.16 (m, 1H), 4.12 (d, 1H), 4.04 - 3.95 (m, 1H), 3.86 (d, 1H), 3.69 (s, 1H), 3.61 - 3.49 (m, 1H), 3.10 - 2.97 (m, 1H), 2.82 - 2.69 (m, 1H), 2.68 - 2.52 (m, 2H), 2.36 - 2.24 (m, 1H), 2.18 (d, 1H), 1.99 - 1.68 (m, 5H), 1.52 - 1.33 (m, 3H), 1.28 (d, 1H).

[0201] Example 1.2 [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 To a solution of (S)-N-amino-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (80 mg, 0.23 mmol, 1.0 equiv.) and (S)-tetrahydro-2H-pyran-2-carboxylic acid (91 mg, 0.70 mmol. 3.0 equiv.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (67 mg, 0.35 mmol, 1.5 equiv.) and HOBt (53 mg, 0.35 mmol, 1.5 equiv.) and DIEA (90 mg, 0.70 mmol, 3.0 equiv.) were added. The resulting mixture was stirred at 25° C. for 1 hr. The crude was purified by reverse flash chromatography to give (S)-N-((2 1 S,2 4 S,5 2 R,5 3 S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)tetrahydro-2H-pyran-2-carboxamide (64.4 mg, 61%) was obtained as a solid. LCMS (ESI): m / z [M+H] + = 457. 1H NMR (400MHz, methanol-d4) δ 7.20 - 7.13 (m, 1H), 7.08 (dd, 1H), 6.92 - 6.83 (m, 2H), 5.32 (d, 1H), 5.28 - 5.20 (m, 1H), 4.73 - 4.43 (m, 1H), 4.18 - 4.05 (m, 3H), 3.98 (dd, 1H), 3.87 - 3.76 (m, 2H), 3.70 (d, 1H), 3.58 - 3.47 (m, 2H), 2.83 - 2.68 (m, 1H), 2.64 - 2.51 (m, 1H), 2.36 - 2.11 (m, 2H), 2.07 - 1.99 (m, 1H), 1.98 - 1.76 (m, 5H), 1.71 - 1.53 (m, 4H), 1.52 - 1.37 (m, 4H), 1.33 - 1.23 (m, 1H).

[0202] Example 1.3 [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 To a solution of N-amino-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (200 mg, 0.58 mmol, 1.0 equiv.) and (S)-tetrahydro-2H-furan-2-carboxylic acid (101 mg, 0.87 mmol. 1.5 equiv.), HATU (397 mg, 1.05 mmol, 1.5 equiv.) and N-diisopropylethylamine (113 mg, 0.87 mmol, 1.5 equiv.) were added. The resulting mixture was stirred at 25° C. for 1 hr. The crude was purified by reverse flash chromatography to give (S)-N-((2 1 S,2 4 S,5 2 R,5 3S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)tetrahydrofuran-2-carboxamide (64.4 mg, 61%) was obtained as a solid. LCMS (ESI): m / z [M+H] + = 443. 1 H NMR (400MHz, chloroform-d) δ 7.18 (t, J = 7.4 Hz, 1H), 7.12 - 7.09 (m, 1H), 6.91 - 6.88 (m, 1H), 6.80 - 6.72 (m, 2H), 5.24 - 5.11 (m, 2H), 4.41 - 4.23 (m, 3H), 4.00 - 3.83 (m, 2H), 3.83 (t, J = 9.1 Hz, 1H), 3.73 - 3.70 (m, 2H), 3.60 - 3.51 (m, 1H), 3.42 (dd, J = 8.6, 4.0 Hz, 1H), 2.76 - 2.54 (m, 2H), 2.41 - 2.20 (m, 2H), 2.12 - 2.09 (m, 2H), 1.99 - 1.82 (m, 5H), 1.76 - 1.64 (m, 2H), 1.53 - 1.45 (m, 1H), 1.46 - 1.32 (m, 3H), 1.28 (s, 1H).

[0203] Example 1.4 [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3To a solution of 1-amino-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (80 mg, 0.23 mmol, 1.0 equiv.) and oxetane-3-carboxylic acid (71 mg, 0.70 mmol. 3.0 equiv.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (67 mg, 0.35 mmol, 1.5 equiv.) and HOBt (53 mg, 0.35 mmol, 1.5 equiv.) and DIEA (90 mg, 0.70 mmol, 3.0 equiv.) were added. The resulting mixture was stirred at 25° C. for 1 hr. The crude was purified by reverse flash chromatography to give (N-((2 1 S,2 4 S,5 2 R,5 3 S)-6-Oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)oxetane-3-carboxamide (58 mg, 58%) was obtained as a solid. LCMS (ESI): m / z [M+H] + = 429. 1 H NMR (400MHz, methanol-d4) δ 7.16 - 7.13 (m, 1H), 7.08 (dd, 1H), 6.92 - 6.82 (m, 2H), 5.37 - 5.24 (m, 2H), 4.89 - 4.59 (m, 5H), 4.13 (dd, 1H), 4.05 - 3.91 (m, 1H), 3.86 (ddd, 2H), 3.69 (s, 1H), 3.60 - 3.48 (m, 1H), 2.82 - 2.66 (m, 1H), 2.59 -2.55 (m, 1H), 2.29 - 2.26 (m, 1H), 2.16 (d, 1H), 1.91 (d, 1H), 1.81 (s, 3H), 1.82 - 1.65 (m, 2H), 1.52 - 1.33 (m, 2H), 1.33 - 1.24 (m, 1H).

[0204] Example 1.5 [ka] To a stirred mixture of benzyl 2-hydroxyacetate (21.9 g, 5.0 equiv, 131.6 mmol) in DMF (100 mL) was added NaH (60%, 5.26 g, 5.0 equiv, 131.6 mmol) in portions at 0 °C. The resulting mixture was stirred at 0 °C under nitrogen atmosphere for 30 min. To the above mixture was added 3-bromo-2-fluoro-4-methylpyridine (5.00 g, 1.0 equiv, 26.314 mmol) at room temperature and the resulting mixture was stirred at 80 °C for another 2 hr. The reaction was quenched by adding sat. NH4Cl(aq.) (500 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3x200 mL). The combined organic layers were washed with water (3x300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography to give benzyl 2-((3-bromo-4-methylpyridin-2-yl)oxy)acetate (7.3 g, 83.0%) as an oil. LCMS (ESI): m / z [M+H]+ = 337.

[0205] [ka] To a solution of benzyl (2R,3S)-3-((tert-butoxycarbonyl)amino)-2-(((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)oxy)methyl)piperidine-1-carboxylate (5.00 g, 1.0 equiv., 3.51 mmol) and benzyl 2-((3-bromo-4-methylpyridin-2-yl)oxy)acetate (1.41 g, 1.2 equiv., 4.21 mmol) in 1,4-dioxane (20 mL) and water (5.0 mL) was added Na2CO3 (1.12 g, 3.0 equiv., 10.5 mmol) and Pd(dppf)Cl2 (385 mg, 0.15 equiv., 0.53 mmol). The reaction mixture was stirred under nitrogen atmosphere at 80° C. for 2 hr. The crude was purified by reverse flash chromatography to give benzyl (2R,3S)-2-(((4-(2-(2-(benzyloxy)-2-oxoethoxy)-4-methylpyridin-3-yl)cyclohex-3-en-1-yl)oxy)methyl)-3-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (2.0 g, 80.0%) as an oil.

[0206] [ka] To a solution of benzyl (2R,3S)-2-(((4-(2-(2-(benzyloxy)-2-oxoethoxy)-4-methylpyridin-3-yl)cyclohex-3-en-1-yl)oxy)methyl)-3-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate (2.00 g, 1.0 equiv, 2.86 mmol) in i-PrOH (30 mL) was added Pd / C (152 mg, 0.5 equiv, 1.43 mmol) under nitrogen atmosphere. The resulting mixture was hydrogenated at room temperature for 15 hr under hydrogen atmosphere using a hydrogen balloon. The mixture was filtered through a Celite® (Imerys Minerals California Inc., San Jose, CA) pad and concentrated under reduced pressure to give the crude product. The crude was purified by reverse flash chromatography to give 2-((3-(4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohex-1-en-1-yl)-4-methylpyridin-2-yl)oxy)acetic acid (950 mg, 69.9%) as a solid. LCMS (ESI): m / z [M+H]+ = 477.

[0207] [ka] To a stirred mixture of 2-((3-(4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)piperidin-2-yl)methoxy)cyclohex-1-en-1-yl)-4-methylpyridin-2-yl)oxy)acetic acid (900 mg, 1.0 equiv, 1.89 mmol) and DIEA (734 mg, 3.0 equiv, 5.68 mmol) in MeCN (400 mL) was added HATU (1.08 g, 1.5 equiv, 2.84 mmol) at 25° C. under nitrogen atmosphere. The resulting mixture was stirred at 25° C. for 2 hr. The mixture was concentrated under reduced pressure. The crude was purified by reverse flash chromatography to give tert-butyl((5 2 R,5 3 S,E)-1 4-Methyl-6-oxo-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphane-2 1 -En-5 3 -yl)carbamate (650 mg, 75.1%) was obtained as a solid. LCMS (ESI): m / z [M+H]+ = 469.

[0208] [ka] tert-Butyl ((5 2 R,5 3 S,E)-1 4 -Methyl-6-oxo-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphane-2 1 -En-5 3 To a solution of tert-butyl((2-yl)carbamate (1.2 g, 1.0 equiv, 2.6 mmol) was added Pd / C (0.56 g, 10% Wt, 0.2 equiv, 0.52 mmol). The reaction mixture was stirred under a hydrogen atmosphere for 5 days. The crude was purified by reverse flash chromatography to give tert-butyl((2-yl)carbamate. 1 S,2 4 S,5 2 R,5 3 S)-1 4 -Methyl-6-oxo-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)carbamate (500 mg, 41.0%) was obtained as a solid. LCMS (ESI): m / z [M+H]+ = 461.

[0209] [ka] tert-Butyl ((2 1 S,2 4 S,5 2 R,5 3 S)-1 4-Methyl-6-oxo-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphane-5 3 To a solution of 2-yl)carbamate (400 mg, 1.0 equiv, 0.87 mmol) was added TFA (3 mL). The reaction mixture was stirred at 25° C. under nitrogen atmosphere for 1 hr. The filtrate was concentrated under reduced pressure, and then aqueous Na2CO3 solution was added. The resulting mixture was extracted with dichloromethane (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography to give (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 -Amino-1 4 -Methyl-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphan-6-one (230 mg, 73.5%) was obtained as a solid. LCMS (ESI): m / z [M+H]+ =360.

[0210] [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 -Amino-1 4To a solution of 1,2-methyl-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphan-6-one (50 mg, 1.0 equiv, 0.14 mmol) and (S)-tetrahydrofuran-2-carboxylic acid (19 mg, 1.2 equiv, 0.17 mmol) was added DIEA (36 mg, 2.0 equiv, 0.28 mmol), HOBt (32 mg, 1.5 equiv, 0.21 mmol) and EDC (40 mg, 1.5 equiv, 0.21 mmol). The resulting mixture was stirred at 25° C. for 1.5 hr. The resulting mixture was extracted with DCM (3×20 mL). The combined organic layers were washed with H2O and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC to give (S)-N-((2 1 S,2 4 S,5 2 R,5 3 S)-1 4 -Methyl-6-oxo-3,8-dioxa-1(3,2)-pyridina-5(2,1)-piperidina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)tetrahydrofuran-2-carboxamide (69 mg, 63%) was obtained as a solid. LCMS (ESI): m / z [M+H]+ = 458; 1H NMR (400MHz, methanol-d4) δ 7.81 (dd, J = 5.2, 4.1 Hz, 1H), 6.81 - 6.79 (m, 1H), 5.39 - 5.23 (m, 2H), 4.79 - 4.75 (m, 1H), 4.40 - 4.23 (m, 2H), 4.19 -4.08 (m, 1H), 4.06 - 3.97 (m, 2H), 3.94 - 3.75 (m, 2H), 3.71 (s, 1H), 3.60 - 3.45 (m, 1H), 3.30 - 3.27 (m, 1H), 3.18 - 2.92 (m, 1H), 2.66 - 2.62 (m, 1H), 2.32 (s, 2H), 2.24 - 2.20 (m, 1H), 2.14 - 1.97 (m, 2H), 1.97 - 1.81 (m, 5H), 1.74 - 1.58 (m, 1H), 1.58 - 1.25 (m, 4H), 1.24 - 1.14 (m, 1H).

[0211] Example 1.6 [ka] (2 1 S,2 4 S,5 2 R,5 3 S)-5 3 -Amino-1 6 To a solution of 1,2-methyl-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzen-2(1,4)-cyclohexanacyclooctaphan-6-one (55 mg, 1.0 equiv., 0.15 mmol) and DIEA (30 mg, 1.5 equiv., 0.23 mmol) was added (S)-tetrahydrofuran-2-carboxylic acid (21 mg, 1.2 equiv., 0.18 mmol) and HATU (88 mg, 1.5 equiv., 0.23 mmol). After stirring for 2 hr at 25 °C under nitrogen atmosphere, the resulting mixture was purified by reverse flash chromatography to give (S)-N-((2 1 S,2 4 S,5 2 R,5 3 S)-1 6-Methyl-6-oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzenina-2(1,4)-cyclohexanacyclooctaphane-5 3 -yl)tetrahydrofuran-2-carboxamide (50 mg, 0.11 mmol, 71%) was obtained as a solid. LCMS (ESI): m / z [M+H]+ = 457; 1 H NMR (400MHz, chloroform-d) δ 7.06 (t, J = 7.8 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 6.72 (d, J = 8.8 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 5.28-5.16 (m, 1H), 5.1 - 5.071 (m, 1H), 4.41-4.22 (m, 3H), 4.01-3.90 (m, 2H), 3.89-3.80 (m, 1H), 3.72 - 3.69 (m, 2H), 3.59-3.47 (m, 1H), 3.39 - 3.35 (m, 1H), 3.00-2.89 (m, 1H), 2.77-2.60 (m, 1H), 2.37-2.20 (m, 5H), 2.18-2.05 (m, 2H), 2.02-1.82 (m, 6H), 1.73-1.66 (m, 1H), 1.49-1.36 (m, 3H), 1.29 - 1.26 (m, 1H).

[0212] Example 2: Human OX2R IP1 Assay T-Rex CHO cells stably overexpressing human orexin-2 receptor (OX2R) were induced with 1 μg / mL doxycycline overnight in a T225 flask. 24 hours after induction, cells were lifted with Accutase and plated at 30,000 cells / well in a 384-well proxy plate. Cells were then treated with different test compounds in 1X stimulation buffer containing 10 mM Hepes, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose and 50 mM LiCl, pH 7.4 for 1hr at 37°C. After incubation, the reaction was terminated by the addition of detection mixture, which consisted of IP1-d2 and anti-IP1-cryptate diluted in lysis buffer and 1X stimulation buffer. Plates were incubated at room temperature for 1 hour and then read on an EnVision® multimode plate reader to measure inositol phosphate levels.

[0213] Cisbio IP1 is a cell-based functional assay that quantifies the accumulation of inositol monophosphate (IP), a metabolite released as a result of orexin 2 receptor activation by the phospholipase C-Gq signaling pathway. It is a competitive immunoassay in which IP1 produced by cells upon receptor activation competes with an IP1 analog linked to a d2 fluorophore (acceptor) for binding to an anti-IP1 monoclonal antibody labeled with Eucryptate (donor). The measured HTRF-FRET-based signal is inversely proportional to the IP1 concentration produced.

[0214] EC reported in Table 2 50 Values ​​were obtained according to the human OX2R IP1 assay described above. Data are the mean EC 50 Values ​​± SEM. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7]

[0215] Example 3: Evaluation of wakefulness promotion in Sprague-Dawley rats Electroencephalography (EEG) and electromyography (EMG) are used to assess wake promotion in adult male Sprague-Dawley rats. Under isoflurane anesthesia, all rats (Charles River Laboratories, Raleigh, NC, USA) are implanted intraperitoneally with a telemetry device (F50-EEE, Data Sciences International Inc., MN, USA). For EEG, stainless steel screws are implanted over the frontal and parietal cortices, and a reference screw is placed over the cerebellum. Additionally, electrodes are placed in the neck muscles for EMG. After surgery, rats are given carprofen and allowed to recover for 7-10 days. Rats are habituated to the laboratory for 7 days and maintained on a 12-h light-dark cycle.

[0216] EEG and EMG data are recorded using a DSI telemetry system and Ponemah software (Data Sciences International Inc., MN, USA). Sleep-wake stages are scored in 10-second intervals (epochs) both manually and with Somnivore, a supervised machine learning software platform. After processing, recordings are visually inspected if necessary.

[0217] All test compounds are dissolved in 5% DMSO and suspended in 95% saline with 0.5% methylcellulose and 0.5% tween. Rats are administered during the inactive light phase at Zeitgeber time 5 (ZT5) in a dose volume of 3.33 ml / kg body weight in a crossover design. All compounds are administered orally unless otherwise indicated. Recordings for each rat begin immediately after dosing and continue for 6 hours post-dosing.

[0218] Two key endpoints include wake time and cortical activation time. Wake time is derived from sleep-wake stage analysis. Cortical activation time is based on the duration of elevation of frontal gamma oscillatory activity (30-100 Hz), a key feature of wakefulness, relative to pre-treatment baseline. Mean cortical activation time is computed relative to vehicle treatment for 6 hours following the dosing period.

[0219] While the present invention has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details can be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

1. Formula (IA): 【Chemistry 1】 (In the formula: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C 1 -C 3 Alkylene-NR a R b , C 1 -C 3 Alkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 8 Cycloalkyl, C 1 -C 3 Alkylene-(C 3 -C 8 cycloalkyl), 4-10 membered heterocyclyl, C 1 -C 3 Alkylene-(4-10 membered heterocyclyl), C 6 -C 10 Aryl, C 1 -C 3 Alkylene-(C 6 -C 10 aryl), 5-10 membered heteroaryl and C 1 -C 3 alkylene-(5-10 membered heteroaryl), 1 -C 3 Alkylene-NR a R b , C 1 -C 3 Alkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 8 Cycloalkyl, C 1 -C 3 Alkylene-(C 3 -C 8 cycloalkyl), 4-10 membered heterocyclyl, C 1 -C 3 Alkylene-(4-10 membered heterocyclyl), C 6 -C 10 Aryl, C 1 -C 3 Alkylene-(C 6 -C 10 aryl), 5-10 membered heteroaryl or C 1 -C 3 Alkylene-(5- to 10-membered heteroaryl) is unsubstituted or substituted with one or more of halogen, hydroxyl, C 1 -C 3 Alkyl or C 1 -C 3 alkoxy substituted; T is CR 1 R 2 or O; W is CR 4 R 5 or O; U is CR 6 R 7 and X is CR 8 R 9 and V is CR 3 or N; Y is NR 10 , O or absent; Z is (CR 12 R 13 ) m and Each R is independently halogen, deuterium, hydroxyl, cyano, or unsubstituted C 1 -C 3 Alkyl and C substituted with one or more halogens or deuterium 1 -C 3 selected from the group consisting of alkyl; p is 0, 1, 2, 3 or 4; R a and R b each independently represents H or unsubstituted C 1 -C 3 is alkyl; m is 1, 2, 3 or 4; and additionally: R 1 , R 2 , R 4 and R 5 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; or alternatively, R 2 and R 5 together with the carbon atom to which they are attached form a single bond; R 3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R 3 and R 1 together with the carbon atoms to which they are attached, C 3 -C 5 Forming a cycloalkyl; or alternatively, R 3 and R 4 together with the carbon atoms to which they are attached, C 3 -C 5 Forming a cycloalkyl; R 6 , R 7 , R 8 , R 9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 H, unsubstituted C 1 -C 3 C substituted with alkyl and one or more halogens 1 -C 3 selected from the group consisting of alkyl; Each R 12 and R 13 are independently H, halogen, deuterium, or unsubstituted C 1 -C 3 Alkyl and C substituted with hydroxyl or one or more halogens 1 -C 3 selected from the group consisting of alkyl; R 14 , R 15 and R 16 each independently represents H, unsubstituted C 1 -C 3 C substituted with alkyl or one or more halogens 1 -C 3 selected from the group consisting of alkyl; Each R 17 and R 18 are independently H, unsubstituted C 1 -C 3 C substituted with alkyl or one or more halogens 1 -C 3 alkyl) or a pharma- ceutically acceptable salt thereof.

2. A compound of formula (IA) or a pharma- ceutically acceptable salt thereof, comprising the compound of formula (I): 【Chemistry 1A】 2. The compound of claim 1, which is a compound of the formula:

3. 3. The compound according to claim 1 or 2, wherein n is 1 or 2.

4. 3. The compound of claim 1 or 2, wherein Ring A is phenyl or pyridinyl.

5. 3. The compound of claim 1 or 2, wherein Y is O or absent.

6. T is CR 1 R 2 or O.

7. W is CR 4 R 5 or O.

8. V is CR 3 3. The compound according to claim 1 or 2,

9. T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 3. The compound according to claim 1 or 2,

10. 3. The compound according to claim 1 or 2, wherein m is 1 or 2.

11. Ring A is phenyl and T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 3. The compound according to claim 1 or 2,

12. 12. The compound of claim 11, wherein Y is absent or O.

13. 12. The compound of claim 11, wherein m is 1 or 2.

14. Ring A is pyridinyl and T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 3. The compound according to claim 1 or 2,

15. 15. The compound of claim 14, wherein Y is absent or O.

16. 15. The compound of claim 14, wherein m is 1 or 2.

17. The method of claim 17, wherein E is selected from the group consisting of C(=O)NR a R b , C 1 -C 3 alkylene-NR a R b , C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 3 alkylene-(C 3 -C 8 cycloalkyl), 4- to 10-membered heterocyclyl, C 1 -C 3 alkylene-(4- to 10-membered heterocyclyl), C 6 -C 10 aryl, C 1 -C 3 alkylene-(C 6 -C 10 aryl), 5- to 10-membered heteroaryl and C 1 -C 3 alkylene-(5- to 10-membered heteroaryl), and wherein C 1 -C 3 alkylene-NR a R b , C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 The compound of claim 1 or 2, wherein -C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C10 aryl, C1-C3 alkylene-(C6-C10 aryl), 5- to 10-membered heteroaryl or C1-C3 alkylene-(5- to 10-membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

18. 【Fig. 2-1】 【Chemistry 2-2】 【Chemistry 2-3】 【Chemistry 2-4】 【Chemistry 2-5】 【Chemistry 2-6】 【Chemistry 2-7】 or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

19. Formula (II-A): 【Chemistry 3】 (In the formula: Ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2 or 3; E is NR a R b , C(=O)NR a R b , C 1 -C 3 Alkylene-NR a R b , C 1 -C 3 Alkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 8 Cycloalkyl, C 1 -C 3 Alkylene-(C 3 -C 8 cycloalkyl), 4-10 membered heterocyclyl, C 1 -C 3 Alkylene-(4-10 membered heterocyclyl), C 6 -C 10 Aryl, C 1 -C 3 Alkylene-(C 6 -C 10 aryl), 5-10 membered heteroaryl and C 1 -C 3 alkylene-(5-10 membered heteroaryl), 1 -C 3 Alkylene-NR a R b , C 1 -C 3 Alkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 8 Cycloalkyl, C 1 -C 3 Alkylene-(C 3 -C 8 cycloalkyl), 4-10 membered heterocyclyl, C 1 -C 3 Alkylene-(4-10 membered heterocyclyl), C 6 -C 10 Aryl, C 1 -C 3 Alkylene-(C 6 -C 10 aryl), 5-10 membered heteroaryl or C 1 -C 3 Alkylene-(5- to 10-membered heteroaryl) is unsubstituted or substituted with one or more of halogen, hydroxyl, C 1 -C 3 Alkyl or C 1 -C 3 alkoxy substituted; T is CR 1 R 2 or O; W is CR 4 R 5 or O; U is CR 6 R 7 and X is CR 8 R 9 and V is CR 3 or N; Y is NR 10 , O or absent; Z is (CR 12 R 13 ) m and Each R is independently halogen, deuterium, hydroxyl, cyano, or unsubstituted C 1 -C 3 Alkyl and C substituted with one or more halogens or deuterium 1 -C 3 selected from the group consisting of alkyl; p is 0, 1, 2, 3 or 4; R a and R b each independently represents H or unsubstituted C 1 -C 3 is alkyl; When Y is absent, m is 2, 3, 4, or 5; or Y is NR 10 or when O, m is 1, 2, 3 or 4; and additionally: R 1 , R 2 , R 4 and R 5 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; or alternatively, R 2 and R 5 together with the carbon atom to which they are attached form a single bond; R 3 is selected from the group consisting of H, deuterium, halogen, hydroxyl and cyano; or alternatively, R 3 and R 1 together with the carbon atoms to which they are attached, C 3 -C 5 Forming a cycloalkyl; or alternatively, R 3 and R 4 together with the carbon atoms to which they are attached, C 3 -C 5 Forming a cycloalkyl; R 6 , R 7 , R 8 , R 9 and R 11 are each independently selected from the group consisting of H, hydroxyl, halogen, and deuterium; R 10 H, unsubstituted C 1 -C 3 C substituted with alkyl and one or more halogens 1 -C 3 selected from the group consisting of alkyl; Each R 12 and R 13 are independently H, halogen, deuterium, or unsubstituted C 1 -C 3 Alkyl and C substituted with hydroxyl or one or more halogens 1 -C 3 selected from the group consisting of alkyl; R 14 , R 15 and R 16 each independently represents H, unsubstituted C 1 -C 3 C substituted with alkyl or one or more halogens 1 -C 3 selected from the group consisting of alkyl; Each R 17 and R 18 are independently H, unsubstituted C 1 -C 3 C substituted with alkyl or one or more halogens 1 -C 3 alkyl) or a pharma- ceutically acceptable salt thereof.

20. The compound of formula (II-A) or a pharma- ceutically acceptable salt thereof is represented by the formula (II): 【Chemistry 3A】 20. The compound of claim 19, which is a compound of the formula: or a pharma- ceutically acceptable salt thereof.

21. 21. The compound of claim 19 or 20, wherein n is 1 or 2.

22. 21. The compound of claim 19 or 20, wherein Ring A is phenyl or pyridinyl.

23. 21. The compound of claim 19 or 20, wherein Y is O or absent.

24. T is CR 1 R 2 or O.

25. W is CR 4 R 5 or O.

26. V is CR 3 21. The compound of claim 19 or 20,

27. T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 21. The compound of claim 19 or 20,

28. 21. The compound of claim 19 or 20, wherein m is 2 or 3.

29. Ring A is phenyl and T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 21. The compound of claim 19 or 20,

30. 30. The compound of claim 29, wherein Y is absent or O.

31. 30. The compound of claim 29, wherein m is 2 or 3.

32. Ring A is pyridinyl and T is CR 1 R 2 and W is CR 4 R 5 and V is CR 3 21. The compound of claim 19 or 20,

33. 33. The compound of claim 32, wherein Y is absent or O.

34. 33. The compound of claim 32, wherein m is 2 or 3.

35. The method of claim 35, wherein E is selected from the group consisting of C(=O)NR a R b , C 1 -C 3 alkylene-NR a R b , C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 3 alkylene-(C 3 -C 8 cycloalkyl), 4- to 10-membered heterocyclyl, C 1 -C 3 alkylene-(4- to 10-membered heterocyclyl), C 6 -C 10 aryl, C 1 -C 3 alkylene-(C 6 -C 10 aryl), 5- to 10-membered heteroaryl and C 1 -C 3 alkylene-(5- to 10-membered heteroaryl), and wherein C 1 -C 3 alkylene-NR a R b , C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 21. The compound of claim 19 or 20, wherein -C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, C1-C3 alkylene-(4- to 10-membered heterocyclyl), C6-C10 aryl, C1-C3 alkylene-(C6-C10 aryl), 5- to 10-membered heteroaryl or C1-C3 alkylene-(5- to 10-membered heteroaryl) is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkyl or C1-C3 alkoxyl.

36. 【Fig. 4-1】 【Chemistry 4-2】 【Chemistry 4-3】 【Chemistry 4-4】 【Chemistry 4-5】 【Chemistry 4-6】 or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

37. 20. A pharmaceutical composition comprising a compound of claim 1 or 19, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

38. 40. Use of a compound according to claim 1 or 19, or a pharma- ceutically acceptable salt thereof, or a composition according to claim 37, in the manufacture of a medicament for treating narcolepsy.

39. 40. Use of a compound according to claim 1 or 19, or a pharma- ceutically acceptable salt thereof, or a composition according to claim 37, in the manufacture of a medicament for cataplexy.

40. 40. The composition of claim 37 for use in a method for treating narcolepsy in a subject in need thereof.

41. 40. The composition of claim 37 for use in a method for treating cataplexy in a subject in need thereof.